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The canonical Wnt signaling pathway is known to regulate multiple 
developmental events,including development of the digestive tract. In this study, 
we wanted to systematically analyze the role of the Wnt/β-Catenin signaling 
pathway during early and late phases of endodermal organogenesis. We 
generated a set of putative hormone-inducible activators or repressors of the 
canonical Wnt signaling pathway. Analysis of Wnt target gene expression and 
axis formation assays revealed that only a subset of these GR-fusion proteins is 
indeed inducible. These constructs were overexpressed in the endoderm of 
Xenopus embryos and protein activity was induced before or after specification 
of endodermal precursor cells. Analysis of pancreatic marker gene expression 
revealed that activation as well as repression of canonical Wnt signaling, early 
and late, inhibit exocrine pancreatic development. 
Expression cloning was used to identify novel regulators of early embryonic 
patterning.We indentified Fam132b as a factor that  induces hyperdorsalization 
and secondary axis formation in Xenopus embryos. Analysis of Wnt and BMP 
target gene expression as well as luciferase reporter experiments revealed that 
Fam132b does not regulate Wnt signaling activity, but antagonizes the BMP 
signaling pathway. Fam132b contains a conserved C-terminal C1q domain and 
an N-terminal signal peptide. Overexpression studies in oocytes demonstrate 
that Fam132b is indeed a secreted factor. Analysis of endogenous target gene 
expression and promoter reporter studies indicated that Fam132b selectively 
inhibits BMP and not activin or FGF induced signaling, and that inhibition occurs 
at the extracellular level. Fam132b strongly interacts with BMP type I receptors, 
and weakly with BMP4 itself, as demonstrated by CoIP experiments. Fam132b 
deletion analysis demonstrated that the C1q domain is dispensable for the BMP 
antagonizing activity. Sequence analysis and axis duplication assays revealed 
that Fam132b protein sequence and protein function are only weakly conserved 
in a comparison ofXenopus and other vertebrate species.  
Fam132b is expressed in the ventral blood islands and later in circulating blood 
cells. In animal cap explants Fam132b is induced by Etv2/er71, which is known 
to activate expression of endothelial and hematopoietic genes in this 




Etv2/er71 expressing animal cap explants using multiplex Nanostring nCounter 
analysis revealed that Fam132b can enhance endothelial development at the 
expense of blood cell lineages. 
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1.1 Wnt signaling pathways 
 
The wnt genes encode a large family of secreted glycoproteins with a highly 
conserved cysteine-rich domain (Angers and Moon, 2009; Croce and McClay, 
2008).The term Wnt is composed of the Drosophila segment polarity gene 
wingless (wg) and the mouse proto-oncogene int-1, two genes that have 
independently been discovered and later shown to encode homologous proteins 
(Baker, 1987; Nusse and Varmus, 1982; Rijsewijk et al., 1987; Sharma and 
Chopra, 1976; van Ooyen and Nusse, 1984).  
The Wnt family of proteins can be subdivided into canonical and non-canonical 
ones, depending on their ability to induce specific Wnt dependent signaling 
pathways. Non-canonical Wnt signaling pathways include different types of cell-
cell communication that are mediated via a Wnt signal, but independent of the 
transcriptional co-activator β-Catenin(Habas and Dawid, 2005). The two most 
intensely studied of the non-canonical Wnt signaling pathways are the planar 
cell polarity (PCP) pathway and the Wnt/calcium (Wnt/Ca2+) pathway. The PCP  
pathway plays an important role  in establishing cell polarity and in the control of 
convergent extension movements of cells, while the Wnt/Ca2+ pathway 
mediates cytoskeletal dynamics and cell adhesion through the regulation of 
intracellular calcium levels (Kohn and Moon, 2005; Seifert and Mlodzik, 2007; 
Semenov et al., 2007). 
 
1.1.1 Wnt/β-Catenin signaling 
 
The first Wnt pathway discovered is also referred to as the canonical Wnt 
signaling pathway and it has been shown to be involved in cell fate decisions, 
proliferation and regeneration. Canonical Wnt signal transduction is mediated 
by the activity of the transcriptional co-activator β-Catenin(Clevers and Nusse, 
2012; MacDonald et al., 2009). In the absence of a Wnt signal, cytoplasmic β-




Axin1/2, adenomatous polyposis coli (APC), glycogen synthase kinase 3 
(GSK3β) andcasein kinase 1ε (CK1ε) (MacDonald et al., 2009).  
 
 
Figure 1. Overview of the Wnt/β-Catenin-mediated signaling pathway. In the 
absence of Wnt, a destruction complex is formed in the cytoplasm, which binds, 
phosphorylates and ubiquitinates cytosolic β-Catenin, leading to its proteasomal 
degradation. Lef/Tcf transcription factors interact with transcriptional corepressors and 
suppress target gene transcription. Wnt binding to the Frizzled receptor recruits the 
destruction complex to the membrane. β-Catenin is not further ubiquitinated, and newly 
synthesizesed β-Catenin accumulates in the cytoplasm, transfers to the nucleus and 
replaces corepressors from Lef/Tcf. Transcriptional coactivators are recruited and 
target gene transcription is induced (after Clevers and Nusse, 2012). 
 
In this way, initial N-terminal phosphorylation of β-Catenin mediated by 
CK1εand GSK3β can occur(Amit et al., 2002; Liu et al., 2002; Yost et al., 1996). 
Consequently, β-Catenin is ubiquitinated by β transducing repeat-containing 
protein (βTrCP) and thereby marked for proteasomal degradation (Aberle et al., 




thelymphoid enhancer-binding protein (Lef)/ T-cell factor (Tcf) family associate 
with transcriptional co-repressors, such as Groucho, and prevent prospective 
Wnt/β-Catenin target gene expression (Figure 1), (Cavallo et al., 1998; Roose et 
al., 1998).  
The canonical Wnt signaling pathway can be stimulated by binding of a Wnt 
protein to the extracellular cysteine-rich domain of the seven-transmembrane 
Frizzled receptor(Bhanot et al., 1996; Dann et al., 2001). As a result, Frizzled 
forms a complex with the single-pass transmembrane protein LDL-receptor-
related proteins 5 and 6 (LRP5/6) (Pinson et al., 2000; Tamai et al., 2000). 
Furthermore, the intracellular domain of Frizzled interacts with Dvl, causing the 
recruitment of the destruction complex to the plasma membrane, where Axin 
binds Dvl as well as the cytoplasmic domain of LRP5/6(Chen et al., 2003; 
Fiedler et al., 2011; Mao et al., 2001). The complex becomes saturated by 
phosphorylated β-Catenin and newly synthesized β-Catenin is no longer 
degraded and can accumulate in the cytoplasm(Li et al., 2012). Finally, β-
Catenin transfers into the nucleus, where it displaces Groucho andrecruits other 
transcriptional co-activators, such as histone modifiers CBP and Brg-1 (Stadeli 
et al., 2006). Additionally, BCL9 binds β-Catenin N-terminally and recruits the 
transcriptional co-activator Pygopus 1 and 2, resulting in transcriptional 
activation of Wnt/β-Catenin target genes (Figure 1), (Brack et al., 2009; Schwab 
et al., 2007). 
 
1.2 TGF-β  signaling pathways 
 
The transforming growth factor-beta (TGF-β) superfamily of signaling pathways 
is involved in regulation of many developmental processes, such as 
proliferation, differentiation, and apoptosis (Massague, 1998). More than 40 
signaling proteins, including TGF-βs, Nodal, Activin and bone morphogenetic 
proteins (BMPs), are known to induce canonical Smad-dependent TGF-β 
signaling pathways (Chen et al., 2012; Guo and Wang, 2009). Additionally, 
TGF-β signals can be transmitted Smad-independently by activating the ERK 
MAP kinase (MAPK) signaling pathway (Lee et al., 2007). 
Among the members of the TGF-β family, more than 20 proteins isolated in 




subfamily (Chen et al., 2004). Except for BMP1 and BMP3, which function as 
signaling regulators, BMP proteins activate the BMP signal transduction 
pathway (Gamer et al., 2005; Ge and Greenspan, 2006).  
 
1.2.1 BMP signal transduction pathway 
 
BMP ligands are synthesized as large precursor proteins consisting of an 
amino-terminal prodomain and a C-terminal mature ligand domain. In the 
endoplasmatic reticulum, these precursors associate as homo- or hetero-dimers 
that are processed in the Golgi compartment allowing the release of mature 
dimers of the ligand domains into the extracellular space (Constam and 
Robertson, 1999; Cui et al., 1998). 
The secreted BMP ligand forms heterohexameric complexes with type I and 
type II BMP receptors at the cell surface (Ehrlich et al., 2011). The BMP type II 
receptor has an intrinsic kinase activity and it phosphorylates serine and 
threonine residues in the intracellular GS domain of the BMP type I 
receptor(Miyazono et al., 2010);in consequence, the  kinase activity of the BMP 
type I receptor is stimulated (Figure 2). Sma and Mad related proteins (Smad) 
1, 5, and 8 are substrates for the BMP type I receptor kinase and are called 
receptor-regulated Smads (R-Smads), accordingly. These R-Smads are 
phosphorylated at the SSVS motif in the C-terminal Mad homology 2 (MH2) 
domain(Qin et al., 2001). Phosphorylated R-Smads can complex with the 
cooperating Smad 4 (Co-Smad) via their MH2 domain (Figure 2).  
The complex of R-Smads and Co-Smad can then translocate to the nucleus 
and bind BMP-responsive regulatory DNA regions via their MH1 domain(Ramel 
and Hill, 2012). Depending on the availability of additional transcriptional 
regulators, DNA bound Smad complexes regulate target gene expression 
positively or negatively (Blitz and Cho, 2009). 
Similar to BMP proteins, also other members of the TGF-β family can induce 
signal transduction via activation of serine/threonine receptor kinases and Smad 
proteins. In the classical view the type I activin receptor-like kinases Alk1/2/3/6 
specifically phosphorylate the BMP-specific R-Smads 1/5/8, while TGF-β, 




phosphorylation of R-Smads 2/3 (Massague et al., 2005). However, it has been 
shown that also members of the BMP family have the potential to activate Alk 
4/5/7 (Schmierer and Hill, 2007). Conversely, other studies revealed that TGF-β 
activates both Smad 2/3 and Smad1/5/8 in various cell types (Bharathy et al., 
2008; Daly et al., 2008; Liu et al., 2009). Furthermore, there are 5 known TGF-β 
type II receptors. BMP receptor II (BMPRII) is a receptor that only recognizes 
BMPs, while Activin receptor II (ActRII) and ActRIIb are bound by activin and 
BMPs (Moustakas and Heldin, 2009). Both BMP-mediated and BMP-
independent branches of Smad dependent signaling operate via the common 
Co-Smad 4 (Chen et al., 1997; Liu et al., 1997). 
 
 
Figure 2. BMP signal transduction pathway.The BMP dimer complexes with type I 
and type II BMP receptors. This leads to autophosphorylation of the type I receptor. 
The activated type I receptor phosphorylates BMP receptor-Smad proteins (R-Smads; 
Smad 1, 5, and 8), which then interact with Co-Smad 4 proteins. The Smad complex 
transfers to the nucleus and regulates target gene transcription (after Miyazono et al., 






1.2.2 Regulation of BMP signaling activity 
 
BMPs were originally identified as molecules with the potential to induce bone 
and cartilage formation when implanted at ectopic sites in rats (Urist, 1965). In 
addition to their role in bone formation, BMPs have been shown to regulate 
tooth, kidney, skin, hair, muscle, hematopoietic and neural development 
(Botchkarev and Sharov, 2004; Bracken et al., 2008; Rogers et al., 2009; 
Sadlon et al., 2004; Thesleff, 2003; Wang et al., 2010). To ensure appropriate 
levels of BMP signaling activity spatially and temporally, this pathway has to be 
tightly regulated during development. Several mechanisms are known to 
regulate BMP signaling on the intracellular as well as on the extracellular level 
(Ramel and Hill, 2012; Walsh et al., 2010). 
 
1.2.2.1. Extracellular BMP antagonists 
 
Secreted BMP-binding proteins exhibit several functions, including initial 
activation and release of BMPs, transport of BMP proteins through tissues, and 
reception of the BMP signal (Umulis et al., 2009). Active BMP proteins are 
generated via cleavage of the pre-protein into the prodomain and the mature 
ligand domain. In vitro studies have shown that the cysteine-rich 
transmembrane BMP regulator 1 (CRIM 1) binds and reduces cleavage of the 
BMP pre-protein (Wilkinson et al., 2003). The cleaved prodomain itself can also 
act as a BMP binding protein. Correspondingly, Ge and colleagues could show 
that BMP11 forms a noncovalent latent complex with its cleaved prodomain that 
can be reactivated by the secreted zinc metalloproteinase BMP1/Tolloid (Figure 
3 A), (Ge et al., 2005). 
Extracellular BMP antagonists represent several secreted peptides, which bind 
BMP proteins and prevent their interaction with their specific receptors (Figure 3 
B). The protein sequence of these factors is characterized by conserved 
cysteine-rich (CR) domains that are involved in the formation of characteristic 
cystine knot structures, similar to those of the BMP proteins. There are three 
classes of secreted inhibitory proteins: Noggin, the DAN family, and Chordin 




and vegetally localized protein (Vg)-1, but no other members of the TGF-β 
family of proteins (Smith and Harland, 1992; Zimmerman et al., 1996). Similar to 
Noggin, also Chordin Chd, the vertebrate homologue of Drosophila Short 
Gastrulation Sog, specifically binds and inhibits BMP proteins (Gazzerro and 




Figure 3. Extracellular mechanisms for modulation of BMP signaling activity. (A) 
The BMP ligand is inactivated by binding to the BMP prodomain and can be reactivated 
by metalloprotease activity of BMP1/Tolloid. (B) Secreted BMP antagonists bind the 
BMP protein and prevent ligand/receptor  interaction. (C) Chordin forms a trimeric 
complex with Tsg and BMP and thereby inhibits BMP/receptor interaction.  The 
metalloproteaseTolloid cleaves Chordin, resulting in a release of the BMP 
protein.Tolloid can be bound by Sizzled or Crescent, preventing Tolloid activity. Tsg 
antagonizes BMP signaling by enhancing the formation of the Chordin/BMP complex. 
But it also acts as BMP activator by facilitating Tolloid-mediated cleavage of Chordin. 
(D) BMP3 and Inhibin bind type II TGF-β receptors inhibit signal transduction into the 





Furthermore, Chd-mediated BMP antagonism is regulated by additional 
secreted factors within a complex network (Figure 3 C). The Twisted 
gastrulation protein can regulate Chordin activity positively as well as 
negatively. On the one hand, it promotes the binding of chordin to the BMP 
protein and thereby the formation of a stable BMP inhibitory complex (Plouhinec 
et al., 2011). But on the other hand, it facilitates BMP1/Tolloid mediated 
proteolysis of Chordin, followed by the release of BMP proteins (Gazzerro and 
Canalis, 2006; Oelgeschlager et al., 2000). In contrast, the secreted Frizzled 
related protein (sFRP) Sizzled as well as Crescent, which both are known to 
antagonize Wnt signaling, can bind and inhibit activity of BMP1 and thereby 
enhance Chordin activity (Lee et al., 2006; Misra and Matise, 2010; Muraoka et 
al., 2006; Ploper et al., 2011; Yabe et al., 2003).  
Another group of extracellular BMP antagonist is the DAN family, including 
Gremelin, Sclerostin, Dan, uterine sensitization associated gene (USAG-1), 
Cerberus, Caronte, Coco, protein related to Dan and Cerberus (PRDC) and 
Dante. In contrast to Noggin or Chordin, these factors antagonize BMP 
signaling as well as Activin-, Nodal-, TGf-β or Wnt signaling (Gazzerro and 
Canalis, 2006; Hsu et al., 1998). 
In addition to BMP interacting proteins, BMP signaling can be modulated by 
receptor interacting factors as well. Inhibin and BMP3 have shown to compete 
with BMP or activin for binding to the corresponding TGF-β type II receptor 
(Figure 3 D). While Inhibin can bind ActRII, ActRIIB, and BMPRII, BMP3 was 
shown to antagonize signaling by complex formation with ActRIIB (Gamer et al., 
2005; Wiater and Vale, 2003). In contrast to Inhibin and BMP3, Follistatin and 
Follistatin-like proteins inhibit BMP and activin signaling via direct interaction 
with the complex of ligand and receptor (Figure 3 E). Follistatin was first 
identiefied as a potent inhibitor of activin, but later was shown also to interact 
with several BMP proteins and myostatin (Geng et al., 2011; Iemura et al., 
1998). Additionally, Thompson and colleagues could show that Follistatin 







1.2.2.2. BMP regulation on the receptor or cytoplasmic level 
 
BMP regulation can occur on the receptor level, involving the activity of 
pseudoreceptors. BMP and activin bound protein (BAMBI) is such a 
pseudoreceptor that is structurally related to type I TGF-β and BMP receptors, 
but it lacks the intracellular kinase domain (Figure 4 A). BAMBI associates with 
type I and type II receptors and inhibits activin as well as BMP signaling 
mediated by these receptor kinases (Miyazono et al., 2010; Onichtchouk et al., 
1999). Additionally, some tyrosine kinases, such as TrkC and Ror2 can bind 
type II or type I BMP receptors and inhibit signal transduction(Jin et al., 2007; 
Sammar et al., 2004). In contrast, cytoplasmic cGMP-dependent kinase I (cGKI) 
causes the stimulation of BMP signaling activity by binding and phosphorylation 
of BMPRII (Figure 4 B), (Schwappacher et al., 2009). 
 
 
Figure 4. Intracellular regulation of BMP signaling activity. (A) The pseudoreceptor 
BAMBI interacts with TGF-β receptors and inhibits signal transduction. (B) cGKI binds 
and phosphorylates BMP type II receptors and thereby enhances BMP signaling. (C) 
Smurfs ubiquitinate BMP receptors and R-Smads, leading to their proteasomal 




βreceptors and R-Smads. (E) I-Smads bind to activated type I receptors  and prevent 
R-Smad phosphorylation. Additionally, I-Smads antagonize BMP signaling by the 
formation of transcriptionally inactive complexes with R-Smads . (F)  Transcriptional 
cofactors positively or negatively regulate Smad-mediated transcription of target genes. 
While OAZ stimulates expression of Xvent-2, SNIP1 binds the Smad complex in 
inhibits transcriptional activation by CBP/p300. (A-F) Negative regulators are indicated 
in green; positive regulators are indicated in red. 
 
Intracellularly, BMP signaling can be modulated by inhibitory Smads (I-Smads), 
phophatases, E3 ubiquitin-ligases, and transcriptional cofactors. TheI-Smad 
family consists of Smad 6 and 7 in vertebrates (Figure 4 E). These factors 
stably bind to the intracellular domain of activated BMP or TGF-β type I 
receptors and thereby prevent phosphorylation of R-Smads by the receptor 
(Imamura et al., 1997; Souchelnytskyi et al., 1998). Additionally, Smad 6 can 
compete with Smad 4 for Smad 1 binding, leading to the formation of a 
transcriptionally inactive Smad 6/ Smad 1 complex (Hata et al., 1998).  
Smad ubiquitination regulatory factors (Smurfs) are E3 ubiquitin-ligases that 
cause proteasomal degradation of R-Smads or BMP receptors (Figure 4 C). 
Smurf1 has been shown to specifically target Smads 1 and 5 (Zhu et al., 1999). 
Kavsak and colleagues reported that human Smurf 2 mediates proteasomal 
degradation of activated TGF-β and BMP receptors (Kavsak et al., 2000). 
Furthermore several phosphatases, such as PP1 or PP2a inhibit BMP signaling 
by dephosphorylation of both the receptor and R-Smads (Figure 4 D), (Wrighton 
et al., 2009).  
The biological output of BMP signaling can be further modulated by interaction 
of nuclear SMAD complexes with different transcriptional co-activators or co-
repressors (Figure 4 F). Apart from general transcriptional coactivators,such as 
p300 and CBP, also Olf-1/EBF associated zinc fingerOAZ was identified as 
DNA binding cofactor that stimulates expression of the direct BMP target gene 
Xvent-2(Hata et al., 2000; Liu et al., 2008; Pouponnot et al., 1998). In contrast, 
some transcriptional co-repressors, such as SNIP1 or E1A are known to inhibit 
TGF-β signaling by inhibiting the interaction between Smads and CBP/p300 








1.3 Development of the blood circulatory system in vertebrates 
 
Vertebrate blood can be classified into three main cell lineages: erythrocytes, 
thrombocytes and leukocytes. These blood cells require a functional vascular 
system in such a way as to enable them to circulate through the body and to 
fulfill their cell-type-specific functions, such as gas transport, blood clotting, and 
immune response, respectively (Hartenstein, 2006). During embryogenesis the 
blood circulatory system is one of the first organ systems to develop. In this 
process blood cells and vessels develop simultaneously in close association 
with each other(Risau, 1995). 
 
1.3.1 Development of blood and vessels during Xenopus 
embryogenesis 
 
Vertebrate blood development occurs in 2 waves, termed primitive and 
definitive hematopoiesis. Early primitive blood cell formation produces primarily 
primitive red blood cells that provide the developing embryo with oxygen. In 
contrast, within the second definitive hematopoietic wave hematopoietic stem 
cells (HSCs) give rise to blood cells of all lineages that are required throughout 
the whole life span of the organism (Kau and Turpen, 1983; Tsiftsoglou et al., 
2009). Ciau-Uitz and colleagues obtained evidence that embryonic and adult 
blood cells have distinct origins in Xenopus (Ciau-Uitz et al., 2000). 
Primitive (embryonic) hematopoiesis occurs first in the ventral blood islands 
(VBI) that are located at the ventral side of the embryo and resemble the 
analogous structure of the mammalian extra-embryonic blood islands on the 
yolk sac (Figure 5 A). In contrast, definitive hematopoiesis originates from the 
dorsal lateral plate(DLP) that resembles the analog of the para-aortic 
slanchnopleura or AGM (aorta, gonads, mesonephros) region in other 
vertebrates (Figure 5 A). 
In addition to blood cell formation, the VBI as well as the DLP contribute to the 
development of vascular structures (Figure 5 B). In a process, termed 
vasculogenesis, blood vessels develop de novo by differentiation of 




capillary network. Vasculogenesis is followed by angiogenesis, the formation of 
new blood vessels from these pre-existing calillaries(Levine et al., 2003; Pardali 
et al., 2010; Risau, 1995). While the VBI mainly contribute to the development 
of embryonic vitelline vein network, the main body vessels, such as dorsal aorta 
and posterior cardinal vein derive from the DLP(Cleaver and Krieg, 1998; 
Walmsley et al., 2002). 
 
 
Figure 5. The VBI and the DLP contribute to the formation of primitive and 
definitive blood as well as to the vascular system. (A) The formation of embryonic 
and defintive blood cells occurs spatially and temporally separated. While primitive 
hematopoiesis is initiated in the VBI at the end of neurulation, definitive hematopoiesis 
in the DLP is induced later, at late tailbud stage. (B) At stage 36 the the vitelline vein 
network and the main body vessels (green) have formed and the first differentiated 
embryonic erythrocytes (red) have started to circulate within the vascular network (after 
Levine et al., 2003). da: dorsal aorta; h: heart; isv: intersomitic veins; pcv posterior 
cardinal vein; vbi: ventral blood islands; vit: vitelline veins. 
 
Lineage tracing studies in Xenopus have shown that both, ventral (V) and 
dorsal (D) mesoderm (M) contribute to the future ventral blood islands(Ciau-Uitz 
et al., 2010; Tracey et al., 1998). While the DM contributes to the most anterior 
portion of the VBI, the aVBI, the VM gives rise to the posterior portion, the pVBI 
(Figure 6 A and C). As gastrulation proceeds, involuting mesoderm at the dorsal 
blastopore lip migrates under the roof of the blastocoel and finally meets up with 
the ventral mesodermal leading edge (Figure 6 B). At the end of neurulation, a 
colony of precursor cells is located immediately posterior to the cement gland 
(Figure 6 A), where they differentiate into either the endothelial or the 
hematopoietic lineage, as development proceeds (Ciau-Uitz et al., 2010; 




While cells of the aVBI give rise to a minority of erythrocytes and a large 
number of myeloid cells, the pVBI produces the main portion of embryonic 
erythrocytes, but also leukocytes and a few short term lymphocytes(Ciau-Uitz et 
al., 2010; Costa et al., 2008; Maeno et al., 2012; Tashiro et al., 2006). Terminal 
differentiation of myeloid cells in the aVBI occurs as early as stage 20 and these 
cells start to migrate throughout the embryo by stage 24, long before the 
circulatory system is established(Maeno et al., 2012; Smith et al., 2002). In 
contrast, first erythrocytes differentiate and express embryonic globin genes in 
the VBI at around stage 30 in ananterior to posterior wave (Tsiftsoglou et al., 
2009). The heart starts beating at stage 33/34 and differentiated erythrocytes 
enter the circulatory system by stage 35/36 (Figure 5 B); (Zon, 1995). 
 
 
Figure 6. Ontogeny of the anterior and the posterior portion of the VBI and the 
DLP . (A) The aVBI derive from the dorsal C1 and D1 blastomeres of the 32-cell stage 
embryo. (B) During gastrulation, mesodermal cells, that will form the aVBI, migrate 
along the blastocoel roof from dorsal to ventral. (C) The ventral D4 blastomere gives 
rise to the pVBI. (D) Cells contributing to the DLP and pronephric tissue derive from the 
C3 blastomere of the 32-cell stage embryo. (A-D) modified after Ciau-Uitz et al., 2010). 
 
The DLP is a derivative of the C3 blastomere of the 32 cell-stage Xenopus 




populated by progenitor cells for definitive blood and the main body vessels that 
coexpress endothelial and hematopoietic marker genes (Ciau-Uitz et al., 2000). 
At stage 27, a subpopulation of cells from the DLP that does not express blood 
genes migrates to the midline towards the hypochord where they form the 
dorsal aorta (Cleaver and Krieg, 1998). Later, blood gene expression is again 
detected in cells associated with the floor of the dorsal aorta (Ciau-Uitz et al., 
2000). These hematopoietic cells are thought to be the first adult blood stem 
cells(Ciau-Uitz et al., 2000; Huber and Zon, 1998).  
 
1.3.2 Blood and vascular development from the hemangioblast and 
thehemogenic endothelium 
 
In 1917, Florence Sabin observed that hematopoietic and vascular cells 
develop in close spatial and temporal association with each other in the avian 
model sytem(Sabin, 2002). In 1932, his finding was confirmed by Murray, who 
proposed a model for a common progenitor for both endothelial and 
hematopoietic cell lineages and termed it the hemangioblast(Murray, 1932). 
 
 
Figure 7. Overlapping expression pattern of Xfli-1 and SCL marks hemangioblast 
formation in the VBI and the DLP. At stage 17 SCL and Xfli-1 are coexpressed by a 
cell population immediately posterior to the cement gland (left panel). At stage 26, 
expression of these genes has become mutually exclusivein the VBI, while overlapping 
in the DLP (right panel). Spatial distribution of SCL and Xfli-1 transcripts was 
determined by whole-mount in situ hybridization of stage 17 or stage 26 Xenopus 
embryos, as indicated. Black arrows indicate DLP; red arrows indicate VBI; Green 





Further evidence for the existence of such a bipotential precursor came from 
studies in mouse, showing that endothelial and hematopoietic cells express a 
similar set of genes, includingFlk1, SCL/tal-1, Cbfa2/Runx1/AML1 and 
CD34(Baron, 2001; Walmsley et al., 2002). Consitent with these data, 
Walmsley and colleagues reported that in Xenopusthe endothelial marker Xfli1 
and the hematopoietic marker SCL are coexpressed at the end of neurulation in 
a restricted region posterior to the cement gland, while getting expressed 
mutually exclusive as differentiation into vascular or blood fate proceeds(Figure 
7). At tailbud stage when definitive hematopoiesis gets initiated these factors 




Figure 8. Development of hematopoietic and vascular cell types from the 
hemangioblast. The hemangioblast, specified from mesoderm, is the common 
precursor of both hematopoietic stem cells (HSC) and the angioblast. HSCs 
differentiate into mature blood cell types expressing cell-type specific genes, while 
angioblasts give rise to vascular structures. During further specification of the 
hemangioblast growth factors, receptors, or transcription factors, that are originally 
coexpressed in the hemangioblast like fli-1 and SCL get restricted to either the 
hematopoietic or the angiogenic fate, as indicated (after Crosier et al., 2002 and Martin 




Transient mouse embryonic stem cell (ESC)–derived blast colony forming cells 
(BL-CFCs), give rise to both hematopoietic and vascular cell lineages. 
Therefore it was considered that these cells are the in vitro equivalent of the 
hemangioblast(Choi et al., 1998; Kennedy et al., 2007).  
Furthermore, loss of function studies in mouse revealed that targeted disruption 
of either the endothelial gene Flk1 or the hematopoietic marker SCL in mouse 
caused severe defects in hematopoiesis as  well as in vasculogenesis(Robb et 
al., 1995; Shalaby et al., 1995; Visvader et al., 1998). 
Based on these data, a model has been proposed in which the hemangioblast 
is specified from the mesoderm, followed by angiogenic or hematopoietic 
fatedecision. Factors that are expressed by the hemangioblast become 
restricted to either the hematopoietic stem cell (HSC) or the angioblast, such as 
fli-1 or SCL, respectively (Figure 8), (Walmsley et al., 2002). While the 
angioblast contributes to the formation of the vascular system, hematopoietic 
stem cells can develop into either lymphoid or erythroid-myeloid precursor cells, 
followed by terminal differentiation into the different mature blood cell types, 
such as B-cells, T-cells, myeloperoxidase (mpo) expressing myeloid cells, or 
globin gene expressing erythrocytes (Figure 8), (Crosier et al., 2002; Martin et 
al., 2011). 
While the development of blood cell lineages and vascular cells from the 
common precursor cell, the hemangioblast, appears to be relevant for at least 
primitive hematopoietic events, it is now generally accepted that during 
definitive hematopoiesis HSCs arise from a hemogenic endothelium. The term 
hemogenic endothelium defines specialized vascular endothelial cells that 
aquire blood forming potential (Hirschi, 2012). Using lineage tracing studies in 
mouse, Zovein and colleagues could show that an epithelial VE-cadherin 
expressing cell population in the AGM region gave rise to all blood cell lineages 
in vivo (Zovein et al., 2008). Further evidence came from in vivo dynamic 
imaging studies in mouse and zebrafish that demonstrated the generation 






Wnt and BMP signaling pathways play important roles in multiple aspects of 
embryogenesis. The first aim of this study was to investigate Wnt signaling in 
the context of gut tube patterning in Xenopus. The second goal of this study 
was to analyze biochemical and biological activities of a novel regulator of BMP 
signaling, identified by expression cloning. 
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2. Materials and Methods 
 
2.1 Model Organism 
The African clawed frog Xenopus laevis (X. laevis) was used as a model 




E. coli strain XL1-Blue (RecA1, endA1, gyrA96, thi-1, hsdR17, supE44, relA1, 
lac[F’proAB, ZΔM15, Tn10(Tetr)]c (Stratagene)) was used during this study. 
 
2.3 Chemicals, Buffers, and Media 
 
2.3.1 Chemicals 
The Chemicals were purchased from the following companies: Roth 
(Karlsruhe), Sigma (Munich), Biomol (Hamburg), Applichem (Darmstadt), and 
Biochrom (Berlin). 
 
2.3.2 Buffers and Media 
Buffers were prepared using deionized water (MiliQ). 
 
Alkaline phosphatase buffer (APB) 
100 mM Tris, 50 mM MgCl2, 100 mM NaCl, 0.1 % TWEEN-20; pH 9.0 
 
Bleaching solution 
50 % Formamide, 1 % - 2 % H2O2, in 5 x SSC 
 
Blocking solution 
1 x TBST; 5 % non fat dry milk 
 




50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 2 mM EDTA, 1 mM EGTA, 0.5 % (v/v) 
NP-40, 10 %  (v/v) glycerol, 1 mM NaF, 1 mM β-glycerolphosphate, 1 mM 
Sodium orthovanadate, Complete Protease inhibitor mix EDTA free (1 tablet per 
50 ml of buffer, Roche) 
 
color reaction solution (WMISH) 
80 μg/ml NBT, 175 μg/ml BCIP in APB; pH 9.0 
 
Collagenase-buffer 
82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES; pH 7.5 
 
Cystein solution 
2 % L-Cystein hydrochloride; pH 7.8 
 
500x Dexamethasone (Dex) 
20 mM dexamethasone in ethanol, stored in the dark, stable for up to 3 month 
 
Hybridization Mix (Hyb Mix) 
50% (v/v) Formamide (deionized), 1 mg/ml Torula-RNA (Sigma), 100 μg/ml 
Heparin, 1 x Denhardt’s, 0.1% (v/v) Tween-20, 0.1% (w/v) CHAPS (Sigma), 10 
mM EDTA,  5X SSC 
 
Injection Buffer 
1 x MBS, 1 % Ficoll (Sigma) 
 
Laemmli loading buffer (2 x) 
10 ml 1.5 M Tris (pH 6.8), 12 ml 10 % SDS, 30 ml glycerol, 15 ml β-
mercaptoethanol, 1.8 mg bromphenol blue 
 
Laemmli running buffer (1 x) 
25 mM Tris, 192 mM Glycine, 0.1 % SDS 
 
 




1.5 % (w/v) agar (DIFCO) in liquid LB-medium 
 
Luria-Bertani (LB)-Medium 
1 % (w/v) Bacto-Trypton (DIFCO), 0.5 % (w/v) yeast extract (DIFCO), 1 % (w/v) 
NaCl, pH 7.5 
 
MAB (5 x) 
500 mM maleic acid, 750 mM NaCl; pH 7.5 
 
MBS buffer Salts (10 x) 
880 mM NaCl, 10 mM KCl, 10 mM MgSO4, 50 mM Hepes, 25 mM NaHCO3; pH 
7.8 
 
MBS buffer AC (5 x) 
440 mM NaCl, 5 mM KCl, 4.1 mM MgSO4, 50 mM Hepes, 12 mM NaHCO3, 2.05 
mM CaCl2, 1.65 mM Ca(NO3)2; pH 7.4 
 
MBS buffer (1 x) 
1 x MBS buffer Salts, 0.7 mM CaCl2 
 
MEM (10 x) 
1 M MOPS, 20 mM EGTA, 10 mM MgSO4; pH 7.4 
 
MEMFA (1 x) 
1 x MEM, 4 % formaldehyde 
 
Nile Blue Solution 
0.01 % (w/v) Nile Blue chloride, 89.6 mM Na2HPO4, 10.4 mM NaH2PO4; pH 7.8 
 
Oocyte culture medium (OCM) 
8.4 mg/ml Leibovitz’s L-15 powder (Gibco®), 0.4 mg/ml BSA, 1 mM L-
glutamine, 0.1 mg/ml Penicillin/Streptomycin (Biochrom) in autoclaved H2O 
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PBS (10 x) 
1.75 M NaCl, 1 M KCl, 65 mM Na2HPO4, 18 mM KH2PO4; pH 7.4 
 
Ponceau S Solution 
2 g Ponceau S, 30 g trichloracetic acid, 30 g sulfosalicylic acid acid per 100 ml 
 
Ptw buffer 
0.1 % Tween-20 in 1 x PBS 
 
SSC (20 x) 
3 M NaCl, 0.3 M Sodium citrate, pH 7.4 
 
TAE (Tris/Acetate/EDTA) 
40 mM Tris-Acetate (pH 8.5), 2 mM EDTA 
 
TE-Buffer 
10 mM Tris-HCl (pH 8.8), 1 mM EDTA) 
 
TBST (1 x) 
50 mM Tris, 150 mM NaCl, 0.1 % TWEEN-20; pH 7.5 
 
Transfer Buffer 
2.9 g Glycine, 5.8 g Tris, 0.37 g SDS, 200 mL Methanol per 1 L 
 
X-gal 
40 mg/ml 5-Bromo-4-chloro-3-indolyl-b-D-galactosidase (X-gal) in 
formamide; stored in the dark at -20°C 
 
X-gal staining solution 













The multipurpose expression vector pCS2+ contains the simian 
cytomegalovirus IE94 enhancer/promoter sequence, which is suitable for 
overexpression experiments in Xenopus. The viral SP6 promoter, polylinker 
sequence, and SV40 viral polyadenylation signal allow the in vitro transcription 
of sense polyadenylated mRNA for microinjection(Rupp et al., 1994). 
 
MT/pCS2+ 
pCS2+/MT is a derivative of the pCS2+ vector, that contains a hexameric repeat 
of the Myc epitope tag at the 5’-end of the first polylinker(Rupp et al., 1994). 
This vector allows the expression of myc-tagged proteins. 
 
HA/pCS2+ 
pCS2+/HA is a derivative of the pCS2+ vector, that contains the Human 
influenza hemagglutinin (HA) epitope tag inserted via the XbaI site(Damianitsch 
et al., 2009). This vector allows the expression of HA-tagged proteins. 
 
MT-GFP/pCS2+ 
pCS2+/MT-GFP is a derivative of the pCS2+/MT vector, that contains the S65A 
mutant form of GFP, in-frame with the Myc epitope tags. This vector is a 
suitable system for cloning of N- and/or C-terminally tagged constructs, as well 




MT-GR/pCS2+ is a derivative of the MT/pCS2+ vector, that contains the human 
glucocorticoid receptor domain (GR), in-frame with the Myc epitope tags. This 
vector is a suitable system for cloning of N- and/or C-terminally tagged 
hormone-inducible constructs (Yonglong Chen, unpublished). 




GR/pCS2+ is a derivative of the pCS2+ vector, that contains the human 
glucocorticoid receptor domain (GR). This vector is a suitable system for cloning 
of hormone-inducible constructs (Yonglong Chen, unpublished). 
 
5’GR/pCS2+ 
GR/pCS2+ is a derivative of the pCS2+ vector, that contains the human 
glucocorticoid receptor domain (GR). This vector is a suitable system for cloning 
of N-terminally fused hormone-inducible constructs(Damianitsch, 2008). 
 
pCS107 
The pCS107 vector is a modification of the pCS105 vector . The major 
modification is the functional T7 promoterwhich now reads: 5' 
gcctctcgagcctctcgccctatagtgagtcg 3' the only difference from pCS105 is the 
change of cgcc (optimal bluescript motif) from agaa (Grammer et al., 2000). 
 
pGEM®-T Easy 
pGEM®-T Easy vector is a suitable system for the cloning of PCR products. It contains 
single 3´-T overhangs at the insertion site within the multiple cloning region. 
This cloning region is located within the alpha-peptide coding region of the 
enzyme beta-galactosidase, what allows blue/white screening on indicator 
plates. The pGEM®-T Easy vector contains T7 and SP6 RNA polymerase 
promoters (Promega).  
 
pBluescript KS/SK 
pBluescript KS/SK phagemids (plasmids with a phage origin) are a cloning 
vectors that contain the beta-galctosidase coding region, which is interrupted by 
a polylinker and flanked by T7 and T3 RNA polymerase promoters (Stratagene). 
 
pGL3 
The pGL3 vector contains a modified coding region of the firefly luciferase gene 
and was designed for the analysis of promoter and enhancer sequences or 
DNA-binding proteins in the context of transcriptional regulation (Promega). 
 




The pRL-TK vector contains cDNA encoding Renilla luciferase under control of 
the herpes simplex virus thymidine kinase (HSV-TK) promoter. It is intended for 




The pRL-CMV vector contains cDNA encoding Renilla luciferase under control 
of the cytomegalovirus (CMV) promoter. It is intended for use as an internal 
control reporter in combination with any experimental reporter vector 
(Promega). 
 
2.4.2 Expression constructs and luciferase reporters 
 
The expression construct and luciferase reporters used in this study are 
presented in Table 1. The constructs were linearized and in vitro transcribed as 
indicated in Table 2. 
 
Table 1.Expression constructs and luciferase preporters 
Name Vector Insert Cloning strategy 
βcatS33A -GR GR/pCS2+ 
Human βcatS33A 
fused to human 
GR-LBD 







fused to human 
GR-LBD 
βcatS33A∆TA sequence was 
amplified from βcatS33A-
GR/pCS2+ (Aberle et al., 
1997; Damianitsch, 2008) 
using primers 
βcatS33A_ClaI_fw  and 
βcatS33A_XhoI_rev. PCR 
product was cut with ClaI and 
XhoI and inserted into the 






fused to Herpes 
simplex virus 
VP16 and human 
GR-LBD 
VP16 sequence was amplified 
from VP16/pCS2+ using 
primers VP16_XhoI_fw and 
VP16_XhoI_rev. PCR product 
was cut with XhoI and inserted 
into the same site of 
βcatS33A∆TA-GR vector. 
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with a mutation at 
serine 33 site 
lacking Trans-
activation domain 
fused to the 
human GR-LBD. 
βcatS33Y∆TA sequence was 
amplified from βcatS33Y/ 
pClneo (Morin et al., 
1997)using primers 
βcatS33A_ClaI_fw  and 
βcatS33A_XhoI_rev. PCR 
product was cut with ClaI and 
XhoI and inserted into the 
same site of 5’GR/pCS2+ 











EnR sequence was amplified 
from EnR/pCS2+ (Tiemo 
Klisch, unpublished) using 
primers EnR_XhoI_fw and 
EnR_XhoI_rev. PCR product 
was cut with XhoI and inserted 






domain fused to 
human GR-LBD. 
∆NTcf3 sequence was 
amplified from ∆NTcf3/pT7T 
(Molenaar et al., 1996) using 
primers dNTCF3_EcoRI_fw 
and dNTCF3_XhoI_rev. PCR 
product was cut with EcoRI 
and XhoI and inserted into the 
same site of 5’GR/pCS2+ 




lacking the CtBP 
binding domain 
fused to human 
GR-LBD. 
Tcf3∆C sequence was 
amplified from Tcf3∆C/ pCS2+ 
(Pukrop et al., 2001) using 
primers TCF3AdC_EcoRI_fw 
and TCF3-AdC_XhoI_rev. 
PCR product was cut with 
EcoRI/XhoI and inserted into 








fused to human 
GR-LBD. 
Tcf3∆HMG sequence was cut 
off from Tcf3∆HMG/pCS2+ 
(Pukrop, unpublished) using 
EcoRI/XhoI and inserted into 








fused to human 
GR-LBD. 
Tcf3∆HMG sequence was cut 
off from Tcf3∆HMG/pCS2+ 
(Pukrop, unpublished) using 
EcoRI/XhoI and inserted into 
the same site of GR/pCS2+ 
vector. 
Lef1-GR GR/pCS2+ mouse full-length (Behrens et al., 1996; 
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Name Vector Insert Cloning strategy 







domain fused to 
human GR-LBD. 




Chimeric fusion of 
the Lef1 DNA 
binding domain 
fused to Herpes 
simplex virus 
VP16 and human 
GR.LBD 


















(Behrens et al., 1996) 





































(Gilchrist et al., 2004) 
Materials and Methods  
27 
 














































































(Gilchrist et al., 2004) 
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XtFam132b sequence was 
amplified from 
TTpA078f11/pCS107(Gilchrist 
et al., 2004) using primers 
fam132b_BamHI_fw and 
fam132b_XhoI_rev. PCR 
product was cut with 
BamHI/XhoI and inserted into 










Wnt8 fused to MT 



















(Smith and Harland, 1992) 
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(Isaacs et al., 1994) 






to HA tag 





PCR product was cut with 
EcoRI/XhoI and inserted into 












related protein 5 
fused to HA tag 




laevis Alk3 BMP 
type I receptor 
with the mutation 
Glu228Asp 
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Name Vector Insert Cloning strategy 
fam132bΔStop_ClaI_rev. PCR 
product was cut with 
BamHI/ClaI and inserted into 










to MT and GR-
LBD 
XtFam132b sequence was cut 
off from XtFam132b-
MT/pCS2+ using BamHII/ClaI 
and inserted into the same site 
of MT-GR/pCS2+ vector. 
Alk2-HA HA/pCS2+ 
Xenopus laevis 
Alk2 BMP type I 
receptor fused to 
HA tag 
(Aramaki et al., 2010) 
Alk3-HA HA/pCS2+ 
Xenopus laevis 
Alk3 BMP type I 
receptor fused to 
HA tag 
(Aramaki et al., 2010) 
Noggin-MT MT/pCS2+ 
Xenopus laevis 
Noggin fused to 
MT tag 





Noggin_ClaI_rev. PCR product 
was cut with ClaI and inserted 






protein 4 fused to 
HA tag 









was amplified from 
XtFam132b/pCS2+ using 
primers famSP_BamHI_fw and 
intfam_XhoI_rev. PCR product 
was cut with EcoRI/XhoI and 









was amplified from 
XtFam132b/pCS2+. N-terminal 




product was cut with 
BamHI/EcoRI. C-terminal C1q 
domain was ampliefied using 
primers C1q_EcoRI_fw and 
fam132b_XhoI_rev. PCR 
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Name Vector Insert Cloning strategy 
product was cut with 
EcoRI/XhoI. Both fragments 
were inserted into the 







XtFam132a sequence  was 
ampliefied from 
XtFam132a/pCS108 (Source 
Bioscience Life Science; 
IMAGE ID: 7603110) using 
primers Xtfam132a_EcoRI_fw 
and Xtfam132a_XhoI_rev. 
PCR product was cut with 
EcoRI/XhoI and inserted into 





MmFam132b sequence  was 
ampliefied from 
MmFam132b/pYX-Asc 
(Source Bioscience Life 




product was cut with 
EcoRI/XhoI and inserted into 











Partial XlFam132b sequence 
was cloned from X. laevis st 
37/38 cDNA using primers 
fam132b_E3_fw and 
fam132b_E5_rev. PCR 
product was cloned into 
pGEM-T®Easy vector. Based 
on sequence analysis of the 
PCR fragment gene specific 
primers 5’RACE_fam132b and 
3’RACE_fam132b were 
generated and used for RACE-
PCR using X. laevis st 37/38 
cDNA. 3’ and 5’RACE 
fragments were inserted into 
pGEM-T®Easy vector. Based 
on sequence analysis of these 
fragments, cloning primers 
fam132b_CDS_EcoRI_fw and 
fam132b_CDS_XbaI_rev were 
generated and used for cloning 
of the XlFam132b coding 
sequence from X. laevis st 
37/38 cDNA. PCR product was 
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Name Vector Insert Cloning strategy 
cutwith EcoRI/XbaI and 
inserted into the same site of 
pCS2+ vector. 




XlFam132b sequence was cut 
off from XlFam132b/pCS2+ 
using EcoRI/XbaI and inserted 
into the same site of pBluskript 
SK vector. 
SCL pGEM-T Xenopus laevis SCL (Neuhaus et al., 2010) 
mpo pCMV-Sport6 Xenopus laevis myeloperoxidase (Smith et al., 2002) 
LMO-2A pCMV-Sport6 
Xenopus laevis 
LIM domain only 
2 
(Mead et al., 2001) 
α-Globin pSPT18 Xenopus laevis α-Globin (Neuhaus et al., 2010) 






















BamHI_rev. PCR product was 
cut with BamHI and inserted 
into the same site of MT-
GFP/pCS2+ vector. 
Etv2/er71 pCS2+ Xenopus laevis Etv2/er71 
etv2/er71sequence was cloned 
from Etv2/pBlueskript SK 
(Salanga et al., 2010)using 
primers etv2_ClaI_fw and 
etv2_XhoI_rev. PCR product 
was cut with ClaI/XhoI and 




Table 2.Linearization of DNA constructs and in vitro transcription 
Name 
sense RNA antisense RNA 
cut polymerize cut polymerize 
βcatS33A-∆TA-GR NotI SP6   
βcatS33A∆TA-VP16-
GR ApaI SP6   
GR- βcatS33AY NotI SP6   
βcatS33A∆TA-EnR-
GR ApaI SP6   




sense RNA antisense RNA 
cut polymerize cut polymerize 
GR-∆NTcf3 NotI SP6   
Tcf3∆C-GR NotI SP6   
GR-Tcf3∆HMG NotI SP6   
Tcf3∆HMG-GR NotI SP6   
Lef1-GR NotI SP6   
Lef∆BD-GR NotI SP6   
Lef∆N-VP16-GR XhoI SP6   
EnR-Lef1-GR EcoRV SP6   
PDIp   BamHI T7 
TTpA072o12 NotI SP6   
TTpA074b10 NotI SP6   
TTpA074h13 NotI SP6   
TTpA075c05 NotI SP6   
TTpA075j02 NotI SP6   
TTpA075o18 NotI SP6   
TTpA076d05 NotI SP6   
TTpA076k21 NotI SP6   
TTpA077b02 NotI SP6   
TTpA078d11 NotI SP6   
TTpA078h06 NotI SP6   
TTpA078l11 NotI SP6   
TTpA073i18 NotI SP6   
TTpA074b19 NotI SP6   
TTpA074l15 NotI SP6   
TTpA075f20 NotI SP6   
TTpA075l15 NotI SP6   
TTpA076b06 NotI SP6   
TTpA076j03 NotI SP6   
TTpA076l10 NotI SP6   
TTpA077e08 NotI SP6   
TTpA078f11 NotI SP6   
TTpA078k07 NotI SP6   




sense RNA antisense RNA 
cut polymerize cut polymerize 
TTpA078m10 NotI SP6   
XtFam132b NotI SP6   
tBR EcoRI SP6   
MT-Wnt8 NotI SP6   
Noggin NotI SP6   
BMP4 BamHI SP6   
BMP2 EcoRI SP6   
eFGF AccI SP6   
Activin XbaI SP6   
Fam132b-HA NotI SP6   
Su(H)-HA NotI SP6   
sFRP5-HA NotI SP6   
caBMPR NotI SP6   
XtFam132b-MT NotI SP6   
XtFam132b-MT-GR NotI SP6   
Alk2-HA NotI SP6   
Alk3-HA NotI SP6   
Noggin-MT NotI SP6   
BMP4-HA Asp718 SP6   
XtFam132b-ΔC1q NotI SP6   
XtFam132b-Δint NotI SP6   
DrFam132b NotI SP6   
MmFam132b NotI SP6   
XtFam132a NotI SP6   
XlFam132b NotI SP6   
SCL   XhoI SP6 
mpo   SalI T7 
LMO-2A   SalI T7 
α-Globin   PstI T7 
ami   EcoRI T7 
5’UTR-XlFam132b -
MT-GFP NotI SP6   
Etv2/er71 NotI SP6   





The oligonucleotides (primers) were purchased from Sigma-Aldrich Chemie. 
 
2.5.1 Sequencing primers 
 
The sequences of sequencing primers used in this study are indicated in 5’→3’ 
direction. 
 
SP6     TTAGGTGACACTATAGAATAC 
T3     AATTAACCCTCACTAAAGGG 
T7 (pCS2+)    TCTACGTAATACGACTCACTATAG 
T7 (pGEM-T)   TAATACGACTCACTATAGGGCGA 
SP6 (pCMV-Sport6)  CTATTTAGGTGACACTATAG 
T7 (pCMV-Sport6)   TAATACGACTCACGTATAGGG 
5’RACE_fam132b_1  GACTGTAACTGTGATGTGTAGCAGGTGC 
5’RACE_fam132b_2  GCAACTGCAGGAAATGATGGA 
 
2.5.2 Cloning primers 
 
The sequences of cloning primers are indicated in 5’→3’ direction (the digestion 
enzyme site is underlined). 
 
EnR_XhoI_fw   CACTCGAGATGGCCCTGGAG 
EnR_XhoI_rev   CTCTCGAGTATGTCGCTTTCCTCCTC 
βcatS33A_ClaI_fw   CATCGATATGGCTACTCAAGCTGACC 
βcatS33A_XhoI_rev  GACTCGAGCTGAGCAAGTTCACAG 
VP16_XhoI_fw   GACTCGAGTTAGCCCCCCCGAC 
VP16_XhoI_rev   CACTCGAGCCCACCGTACTCGTC 
dNTCF3_EcoRI_fw  CTGAATTCATGGCCATCGATG 
dNTCF3_XhoI_rev   CTTCTCGAGGTCACTGGATTTG 
TCF3-AdC_EcoRI_fw  ACGAATTCATGCCTCAGCTCAA 
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TCF3-AdC_XhoI_rev  GTCTCGAGGTTTTCCATCTCAGG 
fam132b_BamHI_fw  GTGGATCCATGGATGCAGAGTACAAG 
fam132b_XhoI_rev  GTCTCGAGTCATTGTCCAAGAAGCAC 
fam132b_EcoRI_fw  GTGAATTCATGGATGCAGAGTACAAGC 
fam132bΔstop_XhoI_rev  GTCTCGAGTTGTCCAAGAAGCAC 
famSP_BamHI_fw   TTGGATCCATGGATGCAGAGTA 
fam132bΔStop_ClaI_rev  GTATCGATGTTGTCCAAGAAGCAC 
Noggin_ClaI_fw   GCATCGATATGGATCATTCCCAGT 
Noggin_ClaI_rev   TTATCGATTGCATGAGCATTTGC 
intfam_XhoI_rev   TTCTCGAGCTATCTGTTGAATGAGC 
famSP_EcoRI_rev   TTGAATTCGTTCTTGTGGGTACAG 
C1q_EcoRI_fw   TTGAATTCTCATTCAACAGAGGAGCAG 
fam132b_E3_fw   ATGTCGCCGTGGCCCTAT 
fam132b_E5_rev   CAATATTCAGTCTTGAATTGAAAGC 
5’RACE_fam132b   GACTGTAACTGTGATGTGTAGCAGGTGC 
3’RACE_fam132b   ACTTGTCTCTGCAACAAACCAGCCAG 
fam132b_CDS_EcoRI_fw TAGAATTCATGGATGCCGAATACA 
fam132b_CDS_XbaI_rev  TATCTAGATCATTGTCCGAGCAGC 
Xtfam132a_EcoRI_fw  CTGAATTCATGAGGTGTTGGGTA 
Xtfam132a_XhoI_rev  CTCTCGAGTTAAAGACCCATAAG 
Mmfam132b_EcoRI_fw  CTGAATTCATGGCCTCGACCC 
Mmfam132b_XhoI_rev  CTCTCGAGTCACAGGCCCAGG 
5’UTR-Xlfam132b_fw_BamHI GTGGATCCAGGGAAAGTAATTGG 
5’UTR-Xlfam132b_ BamHI_rev TTGGATCCAGGGATCGGCTTG 
etv2_ClaI_fw   CTATCGATATGGATCCCAGTATCTACTACT 
etv2_XhoI_rev   CCCTCGAGTTATTGAATCCTGG 
 
2.5.3 RT-PCR primers 
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Table 3.RT-PCR primers 
Target 















































































2.5.4 Morpholino oligonucleotides 
 
Antisense Morpholino oligonucleotides (Morpholinos, MO) were purchased from 
Gene Tools, LLC (Philomath, USA). Morpholinos were dissolved in RNAse-free 
water to a 1μM concentration. The sequences of the antisense Morpholinos 
used in this study are presented in Table 4. 
 
Table 4. Anisense Morpholino oligonucleotides 








































The antibodies used during this study are presented in Table 5. 
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anti goat IgG (H + 








anti mouse IgG (H 




2.7 Chemical transformation and cultivation of bacterial cells 
 
For chemical transformation 200 μl of chemically competent E.coli XL1blue cells 
were thawed on ice, mixed with 10 μl of the ligation mix or 100 ng of plasmid 
DNA, incubated for 30 min on ice and heat-shocked for 90 sec at 42°C, then left 
for 3 min on ice. 800 µl of LB-medium were added to the cells and the culture 
was incubated at 37°C for 30 to 45 h min. Bacterial pellets were seeded on LB 
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agar plates supplemented with 0.1 mg/ml ampicillin (Biomol) for the selection of 
transformed cells. LB-agar plates were incubated overnight at 37°C(Sambrook, 
2001). 
For preparation of a liquid bacterial culture one single bacterial colony was 
isolated from a bacterial plate and transferred into a sterile Erlenmeyer flask 
filled with 100 ml of LB-medium supplemented with ampicillin. The liquid culture 
was incubated overnight in a 37°C shaker at 220 rpm(Sambrook, 2001). 
 
2.8 DNA methods 
 
2.8.1 Plasmid DNA preparations 
 
Isolation of plasmid DNA in analytical amounts was performed using IllustraTM 
Plasmid Prep Mini Spin Kit (GE Healthcare). For the isolation of plasmid DNA in 
preparative amounts IllustraTM Plasmid Prep Midi Flow Kit (GE Healthcare) 
was used. The DNA isolation was performed according to the manufacturer’s 
instructions. DNA concentrations were measured using the ND-1000 
Spectrophotometer, Coleman Technologies Inc. 
 
2.8.2 DNA restriction digestion 
 
DNA restriction digestion was performed using restriction endonucleases 
purchased from MBI Fermentas according to manufacturer’s instructions. 
 
2.8.3 Agarose gel electrophoresis 
 
DNA or RNA fragments were separated in a horizontal electrical field into 
agarose gel(Sharp et al., 1973). Depending on the expected sizes of DNA/RNA 
fragments, 0.8 to 2% (w/v) agarose gels were prepared in TAE buffer. 0.5 μg/ml 
ethidium bromine was added for visualization of nucleic acids. Before loading 
the gel slots, nucleic acid samples were mixed with DNA loading dye (6x, 
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Ambion). The electrophoresis was run in the standard TAE-running buffer at 
100 V in horizontal electrophoresis chamber. After electrophoresis, DNA/RNA 
bands were visualized using the UV-transilluminator (Herolab) and documented 
with the ChemiDoc video documentation system (EASY view). Standard DNA 
ladders were used to determine the sizes of DNA fragments (High, Middle, or 
Low Range, Fermentas). 
 
2.8.4 Purification of DNA fragments from agarose gel or restriction 
digestion mixture 
 
The purification of DNA fragments from agarose gels or restriction digestion 
mixture was performed with the IllustraTM GFX PCR DNA and Gel Band 
Purification Kit (GE Healthcare) according to manufacturer’s instructions. 
 
2.8.5 cDNA synthesis 
 
MuLV Reverse Transcriptase (Roche) was used to synthesize complementary 
DNA (cDNA) from total RNA, extracted from whole embryos or embryonic 
explants. 
 
Reaction mixture:  1 x  Go Taq® Flexi Buffer (Promega) 
5 mM   MgCl2 (Fermentas) 
1 mM   dNTP mix (Thermo Scientific) 
5 ng/µl   Random primers (Invitrogen) 
15 ng/µl  total RNA 
    0.8 U/µl Ribolock RNase Inhibitor (Fermentas) 
    2 U/µl  MulV Reverse transcriptase (Roche) 
     
After an initial incubation for 10 min at 20°C to anneal the Random primers, 
cDNA synthesis was carried out for 1 hour at 42°C and terminated by heating to 
95°C for 5 min. 
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For semi-quantative RT-PCR, 5 μl cDNA were used in a total volume of 25 μl 
containing 0.2 µM RT primers each, 1.5 mM MgCl2, 0.5 U Go Taq® polymerase 
in 1 x Green Go Taq® Flexi Buffer (Promega). To test for DNA contaminations 
H4 RT-PCR was carried out using total RNA. H4 RT-PCR on cDNA templates 
served as a control for equal cDNA concentrations. 
 
2.8.6.2. Cloning PCR 
 
The High Fidelity PCR enzyme Mix (Fermentas) was used for PCR followed by 
molecular cloning of the amplified fragments 
 
PCR reaction mixture:  
1 x  High Fidelity PCR Buffer with 15 mM MgCl2 
0.2mM  dNTP mix (Thermo Scientific) 
0.75 µM  primers each 
0.1 ng/µl  matrix DNA  
0.1 U/µl  High Fidelity PCR enzyme Mix (Fermentas)  
    add HPLC-water (ROTH) 
 
The following cycling conditions were used for DNA fragments amplification: 
   
Initial denaturation  95°C  5 min 
Denaturation   95°C  45 sec 
Primer annealing  x°C  45 sec  30 cycles 
Elongation   72°C  1 min/1 kb 
Final elongation  72°C  5 min 
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2.8.6.3. 3’ RACE and 5’RACE PCR 
 
For the isolation of 5’- and 3’sequences of target transcripts first-strand cDNA 
synthesis and RACE PCRs were performed using the SMART RACE cDNA 
Amplification Kit (Clontech) according to manufacturer’s instructions. 
 
2.8.6.4. Site directed Mutagenesis 
 
To introduce specific mutations at a target site within one sequence the 
QuikChange® XL Site-Directed Mutagenesis Kit (Stratagene) was used. Design 
of mutagenic primers, mutagenesis reaction, and digest of methylated, 
nonmutated DNA template were performed according to manufacturer’s 
instructions. Afterwards E.coli XL1blue cells were transformed with 20 µl of the 
reaction mix (described in paragraph 2.7). 
 
2.8.7 DNA ligation 
 
To ligate DNA fragments T4 DNA ligase (Fermentas) was used according to 
manufacturer’s instructions. For the ligation a vector and an insert were taken in 
1 to 3 molar ratio. The total amount of vector DNA was 50 ng. For 10 μl of a 
single reaction mixture 5 U T4 DNA ligase were used. The ligation was 
performed overnight at 16°C. E.coli XL1blue cells were transformed with 10 µl 
of the ligation mixture (described in paragraph 2.7). 
 
2.8.8 DNA sequencing analysis 
 
The Dye-termination sequencing method, which is the modification of Sanger 
chain-termination sequencing, was used (Sanger et al. 1977). For preparation 
of the sequencing PCR mixture the Big DyeTM Terminator Kit (Applied 
Biosystems) was used according to the manufacturer’s instructions. 
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Sequencing PCR mixture:  200 - 400 ng DNA matrix  
1.5 μl   Seq mix 
     1.5 μl  Seq buffer 
     8 pmol Seq. primer 
add HPLC water to 10 μl 
 
Sequencing PCR conditions: 95°C  2 min 
     95°C  30 sec 
     56°C  20 sec 25 cycles 
     60°C  4 min 
 
To purify the DNA fragments from the sequencing reaction the following 
components were added to 10 µl of the reaction mixture: 
 
1μl  125 mM EDTA (pH 8.0) 
1μl  3 M sodium acetate (pH 5.4) 
 50 μl   100% ethanol 
 
The samples were incubated for 5 min at room temperature, then centrifuged 
for 15 min at 14000 rpm. The DNA pellets were washed with 70 μl of 70% 
ethanol, air-dried and dissolved in 15 μl of HiDiTM buffer (Applied Biosystems). 
Automated sequencing was carried out by the ABI 3100 Automated Capillary 
DNA Sequencer (Applied Biosystems). 
 
2.9 RNA methods 
 
2.9.1 In vitro synthesis of capped sense mRNA 
 
In vitro synthesis of capped sense mRNAs for microinjections into Xenopus 
embryos and oocytes was performed with using the SP6 or T7 mMessage 
mMachine KitsTM (Ambion) according to the manufacturer’s protocol. 20 μl of 
reaction mixture containing 0.5 - 1 μg of linearized DNA template was incubated 
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for 3 hours at 37°C, followed by template DNA digestion for 30 min at 37°C 
using 5 U of Turbo DNaseI (Ambion). Synthesized RNA was purified using the 
IllustraTM RNAspin Mini RNA Isolation Kit (GE Healthcare). RNA concentrations 
were determined using the ND-1000 Spectrophotometer (Coleman 
Technologies Inc.). 
 
2.9.2 In vitro synthesis of labeled antisense RNA 
 
The following reaction mixture was used for the synthesis of digoxgenin-labeled 
antisense RNA for whole mount in situ hybridization: 
 
1 x  transcription buffer (Fermentas) 
1 mM  rATP (Boehringer) 
1 mM  rCTP (Boehringer) 
1 mM  rGTP (Boehringer) 
0.64 mM rUTP (Boehringer) 
0.36 mM digoxigenin-rUTP (Boehringer) 
0.03 µM DTT 
1.6 U/µl Ribolock RNase Inhibitor (Fermentas) 
2 µg  linearized DNA template 
1.2 U/µl  T3, T7 or Sp6 polymerase (Fermentas) 
add RNase-free water 
 
The reaction mixture was incubated for 3 hours at 37°C, followed by template 
DNA digestion for 30 min at 37°C using 0.2 U/µl Turbo DNaseI (Ambion). 
Synthesized digoxgenin-labeled RNA was purified with the RNeasyTM Mini Kit 
(Quiagen) according to manufacturer’s instructions.The RNA was eluted twice 
with 50 μlRNase-free H2O and stored in Hybridization Mix (see whole mount in 
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2.9.3 Total RNA extraction from whole embryos and embryonic explants 
 
For extraction of total RNA used for cDNA synthesis and RT-PCR 5 whole 
embryos, 10 mesodermal explants, or 50 – 100 ectodermal explants were fixed 
in N2liq and macerated in 400 µl peqGOLD TriFast reagent (peQlab) using a 
sterile Omnican® 40 syringe (Braun). After 30 sec of vortexing 80 µl of 
Chloroform (Roth) were added and the sample was vortexed for 30 sec, 
followed by 10 min of centrifugation. The upper phase was transferred into a 
new tube and mixed with another 200 µl of Chloroform (Roth) by vortexing for 
30 sec. After a second centrifugation step of 5 min the upper phase was 
transferred into a new tube and precipitation of nucleic acids was carried out by 
the addition of 200 µl of 2-Propanol (Roth), vortexing and overnight incubation 
at -20°C. After 30 min of centrifugation the nucleic acid pellet was washed using 
400 µl of 70 % ethanol. The air-dried pellet was dissolved in 12.5 µl of RNase-
free water. For DNA digestion and purification of RNA the RNAqueous-Micro Kit 
(Ambion) was used according to manufacturer’s instructions. After a final 
incubation of the extracted RNA at 70°C, RNA concentrations were determined 
using the ND-1000 Spectrophotometer (Coleman Technologies Inc.) and RNA 
samples were stored at    -80°C. 
For extraction of total RNA used for 3’ RACE and 5’RACE PCR 5 embryos were 
fixed in N2 liq and homogenized in 500 µl 0.2 mg/ml proteinase K/ 1 x extraction 
buffer using a sterile Omnican® 40 syringe (Braun). After 45 min of incubation 
at 45°C RNA extraction was carried by addition of the following reagents:  
 
1 vol Roti®-Aqua-Phenol/C/I (Roth) 
1 vol Roti®-Aqua-Phenol/C/I (Roth) 
1 vol 24/1 Chloroform/Isoamoyl alcohol 
 
Every extraction step was followed by vortexing, centrifugation for 10 min, and 
transfer of the upper aqueous phase into a new tube. 1 vol of 8 M LiCL was 
added to precipitate RNA by vortexing and overnight incubation at -20°C. After 
30 min of centrifugation the pellet was air-dried and dissolved in 100 µl of 
RNase-free water. Another precipitation step was carried out by addition of 0.2 
vol 5 M ammonium acetate and 5 vol of 100 % ethanol, followed by 30 min 
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incubation at -20°C. After 30 min of centrifugation the pellet was washed in 80 
% ethanol, air-dried and dissolved in 40 µl of RNase-free water. To completely 
remove residual genomic DNA 5µl 10 x DNase buffer (Fermentas), 1 µl 1U/µl 
RNase-free DNase I (Fermentas) and 4 µl RNase-free water were added and 
incubated for 30 min at 37°C. After addition of 50 µl RNase-free water 3 RNA 
precipitation steps followed using 1 vol Roti®-Aqua-Phenol/C/I (Roth), 1 vol 
24/1 Chloroform/Isoamoyl alcohol, and 0.2 vol 5 M ammonium acetate and 5 vol 
of 100 % ethanol, as described above. After another washing step using 80 % 
ethanol the air-dried RNA pellet was dissolved in 50 µl RNase-free water. Every 
centrifugation step was carried out at 4°C and 13000 rpm. RNA concentrations 
were determined using the ND-1000 Spectrophotometer (Coleman 
Technologies Inc.) and RNA samples were stored at -80°C. 
 
2.10 Protein methods 
 
2.10.1 Protein isolation from embryos and oocytes 
 
For protein isolation 20 embryos or oocytes were fixed in N2 liq and macerated in 
500 µl CoIP buffer using a sterile Omnican® 40 syringe (Braun). Lysates were 
centrifuged for 15 min at 4°C and 13000 rpm and the supernatant was either 
used for Co-immunoprecipitation, or samles were prepared for SDS-PAGE. 
 
2.10.2 Protein isolation from oocyte culture medium 
 
5 vol of ice cold Aceton were added to the oocyte culture medium and protein 
precipitation was carried out on ice. After centrifugation for 15 min at 4°C and 
13000 rpm the protein pellet was washed in 1 ml ice cold Aceton and dried at 
40°C to 50°C. The pellet was then dissolved in 30 µl of CoIP buffer and the 
protein sample was prepared for SDS-PAGE. 
 
 





Co-immunoprecipitation (CoIP) in Xenopus embryos was performed as 
described. Xenopus embryos were injected with mRNAs coding for tagged 
proteins animally into both blastomeres at the two cell stage and cultured until 
stage 10.5 to 11.5. After protein isolation, described in paragraph 2.10.1, an 
input aliquot was taken from each sample and prepared for SDS-PAGE. Protein 
containing supernatants were incubated for 30 min with 15 μl Protein A 
Sepharose (Amersham) for pre-clearing. After centrifugation supernatants were 
transferred into fresh tubes, antibodies were added, and the samples were 
incubated for two hours, followed by two hours incubation with 15 μl Protein A 
Sepharose (Amersham). Preclearing- and CoIP-pellets were washed 5 times for 
5 min with CoIP buffer, resuspended in 10 µl CoIP buffer, and prepared for 
SDS-PAGE. Every incubation and centrifugation step was carried out at 4°C. 
 
2.10.4 TNT (in vitro transcription and translation) 
 
The In vitro transcription and translation-assay and protein detection were 
performed, using the TNT® Coupled Reticulocyte Lysate System (promega) 
and the TranscendTM Chemiluminescent Non-Radioactive Translation Detection 
System (promega). TNT reactions were carried out in volumes of 12.5 µl 
according the manufacturer’s user manual. 
 
2.10.5 Protein electrophoresis under denaturing conditions (SDS-PAGE) 
 
The proteins were separated by SDS polyacrylamid gel electrophoresis 
(Harlow, 1988; Laemmli, 1970). 10 % - 12 % SDS polyacrylamid gels were used 
for the analysis of proteins with distinct molecular weights. Protein samples 
were diluted 1:1 with 2x Laemmli loading buffer and boiled for 3 min at 95°C, 
then applied on the gel. The gel running was performed in 1x Laemmli running 
buffer. At first voltage of 70 V was applied, and once the bromphenol-blue front 
reached the separating gel, the voltage was raised to 120 V. 
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2.10.6 Western Blotting 
 
After SDS-PAGE proteins were transferred to a nitrocellulose membrane (0.45 
μm, Schleicher & Schuell) using semi-dry blotting system(Harlow, 1988). Protein 
transfer was carried out in transfer buffer for 1 h using a voltage of 40 V. After 
transfer, the membrane was blocked with a blocking solution for 1 hour at room 
temperature. Incubation with primary antibody solution was carried out 
overnight at 4°C in blocking solution. Next day the membrane was washed 3 
times for 10 min in blocking solution and the secondary antibodies coupled with 
horse reddish peroxidase (HRP) or fluorescent IRDyes (LI-COR) were applied 
in blocking solution for 1 h at room temperature. The membrane was washed 
again with blocking solution 2 times for 10 min and 1 time in TBST for 10 min. 
The HRP signals were detected with the ECL Kit Super Signal DuraTM West Kit 
(Pierce) on X-raydetection film (Amersham). Fluorescent signals were 
detetected using LI-COR Odyssey Infrared Imaging system. 
 
2.11 Xenopus embryo culture and micromanipulations 
 
2.11.1 Preparation of Xenopus laevis testis 
 
The Xenopus male frog was sacrificed by submerging it in 0.05% benzocaine 
for 30 min at room temperature. The frog was decapitated, the skin flap was 
removed from the belly and an incision into the muscle was performed. The 
testes were removed through the incision together with fat body and detached 
from it. The testes were washed 3 times with 1 x MBS and stored in the 1x MBS 
buffer at 4°C. 
 
2.11.2 Embryo culture and microinjections 
 
Xenopus laevis female frogs were induced to lay eggs by injection of 1000 units 
human chorionic gonadotropin (hCG, Sigma Aldrich) into the dorsal lymph sac, 
approximately 12 hours before desired egg-laying. Laid eggs were in vitro 
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fertilized with minced testis in 0.1 x MBS. Fertilized eggs were treated with 2% 
cyteine hydrochloride, pH 8.0, to remove the jelly coat.The embryos were 
cultured in 0.1 x MBS at 12.5 - 18°C. Albino embryos were stained with Nile 
Blue vital dye for 10 min prior to injection to allow to distinguish animal and 
vegetal poles, as well as different stages of development. Injections were 
performed in injection buffer on a cooling plate (12.5°C). The solutions for 
microinjections were loaded into the glass needles prepared on Leitz Needle 
puller. The Microinjector 5242 (Eppendorf) was used during this study. For 
different purposes injections at 2-, 4- or 8-cell stages were performed. The 
injection volume was 4 nl of injection mixture per blastomere. Injected embryos 
were kept for at least 1 hour in the injection buffer to allow the heeling of 
injection opening and embryos were then transferred into 0.1x MBS. The 
developmental stages were defined according to Nieuwkoop and Faber Normal 
Table of Xenopus laevis (Daudin). 
 
2.11.3 Oocyte culture and microinjection 
 
To isolate oocytes, adult, female Xenopus laevis were operated on ice under 
anesthesia with 0.25% 3-aminobenzoic acid ethyl ester solution (20 min 
anesthesia). Oocytes were separated by treatment with 1 mg/ml liberase 
blendzyme (Roche) in collagenase-buffer and agitation up to 120 min. Oocytes 
were extensively washed using 1x MBS, incubated at 18°C and staged 
according to Dumont, 1972. Stage VI oocytes were injected in in 1 x MBS into 
the vegetal pole, as described for embryo microinjections (2.11.2). Injected 
oocytes were cultivated for 24 hours in oocyte culture medium (OCM) at 18°C. 
After separation of oocyte and OCM fraction, samples were fixed in liquid 
nitrogen for protein isolation. 
 
2.11.4 Xenopus ectodermal and ventral mesodermal explants 
 
For explantation of embryonic tissues the vitteline membrane of Xenopus 
embryos was removed using forceps. And animal caps were explanted at stage 
8 using a ‘gastromaster tip’. Ventral mesodermal tissue was dissected from 
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stage 10.25 embryos using forceps. Embryonic explants were dissected and 
cultivated on 1% agarose-coated Petri dishes in 0,8 x MBS buffer until control 
sibling embryos reached the desired stage of development, fixed in liquid 
Nitrogen, and stored at -80°C (Sive et al., 2000). 
 
2.11.5 Dexamethasone treatment 
 
Embryos were injected with inducible mRNA constructs. Animal caps and 
embryos were treated with fresh 1 x Dexamethasone (DEX)/0.1 x MBS at 
various stages and continuously kept in solution until fixation. 
 
2.12 Xenopus tropicalis “Full-Length” Library Expression 
Screen 
 
For the Expression-cloning RNA pools of 24 individual RNAs derived from a 
Xenopus tropicalis “Full-Length” cDNA Library were injected animally into both 
cells of Xenopus laevis two-cell stage embryos (Gilchrist et al., 2004). Embryos 
were cultivated to tadpole stage and scored for axis formation defects. To 
identify the active clone within one pool, RNA mixtures containing 12, 6, or 1 
individual mRNA of the original pool of 24 were injected and scored for the 
corresponding phenotype. Depending on the number of individual RNA clones 
contributing to the mixture, different RNA concentrations were injected, as 
indicated in Table 6. 
 
Table 6. Total amounts of injected RNAs with respect to pool size 




1 60 and 120 
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2.13 Whole mount in situ hybridization (WMISH) 
 
2.13.1 X-gal staining 
 
Embryos were grown to the desired stage and fixed for 20 min in MEMFA. After 
washing three times for 10 min in 1x PBS, embryos were transferred to X-gal 
staining solution until staining was sufficient, typically 10 to 20 min. The reaction 
was stopped by washing the embryos three times in 1x PBS and afterwards 
fixed in MEMFA for 25 min. For whole mount in situ embryos were dehydrated 
with absolute ethanol and stored at -20°C. 
 
2.13.2 Whole mount in situ hybridization (WMISH) 
 
Whole mount in situ hybridization (WMISH) was performed essentially, as 
described (Harland, 1991; Hollemann and Pieler, 1999)using antisense RNA 
labeled with digoxigenin-11-UTP. All steps were performed at ambient 
temperature with mild shaking. Embryos were rehydrated with the EtOH series 
to PTw, washed three times in PTw for 10 min and subjected to Proteinase K 
treatment to allow better penetration of the RNA probe. Stage 15 embryos were 
incubated for 6 min, later stage embryos were incubated for no longer than 15 
min in Proteinase K. Embryos were washed twice in 0.1 M triethanolamine, pH 
7.5, to stop Proteinase K digestion and acetylated by adding 25 μl acetic 
anhydrite to fresh triethanolamine. After 5 min, another 25 μl acetic anhydrite 
was added. Then embryos were fixed in PTw/MEMFA for 25 min, washed five 
times in PTw, transferred to Hyb Mix and incubated for 5 hr at 65°C in a water 
bath. Hyb Mix was exchanged for the antisense RNA probe and incubated 
overnight at 65°C in a water bath. The next day, the RNA probe was collected 
and stored -20°C for reuse. After washes in Hyb Mix for 10 min at 65°C, three 
times in 2 x SSC for 15 min at 65°C, non-hybridized RNA probe was removed 
by RNase digestion for 1 hour at 37°C in RNase solution. The digested probe 
removed by washing once in 2 x SSC at 37°C and twice 0.2 x SSC at 65°C. 
After exchanging the buffer to MAB, embryos were blocked in MAB/BMB for 20 
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min and MAB/BMB/HS for 40 min to minimize unspecific binding of the 
antibody. The solution was replaced with antibody solution and incubated for 5 
hours. The embryos were washed three times for 10 min with MAB and then 
overnight in MAB. After three rinses with MAB for 5 min, the caps were 
exchanged and the embryos transferred to APB. After three washes in APB for 
5 min each, alkaline phosphatase was detected in color reaction solution. 
Embryos were kept at 4°C in the dark until staining was sufficient. The embryos 
were transferred to 100% Methanol to stop the reaction and to minimize 
background staining. Then embryos were rehydrated with the MeOH series to 





Embryos were washed twice in 5 x SSC and transferred into bleaching solution 
to remove pigmentation of the embryos. Bleached embryos were washed twice 
in 5 x SSC and fixed over night in MEMFA. 
 
2.14 Luciferase assay 
 
Embryos were injected with either 50 pg Siamois-Luc (Brannon et al., 1997) and 
10 pg pRL-TK (Promega) or 8 pg Vent2b-BRE-Luc (Henningfeld et al., 2000) 
and 4 pg pRL-CMV (Promega) reporter DNA in combination with respective 
mRNAs. Gastrula stage embryos were fixed in liquid N2 and stored at -80°C. 
For each sample triplicates of 15 embryos each were analyzed within 1 
independent experiment. The Dual Luciferase Assay Kit (Promega) was used 
for preparation of embryonic lysates and measurement of Firefly and Renilla 
luciferase activity according to the manufacturer's instructions. Measurements 
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2.15 Nanostring nCounter analysis 
 
The quantitative multiplexed gene expression analysis using Nanostring nCounter 
was used according to the manufacturer's instructions;500 ng of total RNA from 
Xenopus embryos or ectodermal explants was applied in 5 µl for a total volume of 
30 µl. The genes analyzed by Nanostring nCounter, accession numbers, target 
regions and the reporter probe sequences are shown in Appendix 6.1. Primary 
gene expression data from Nanostring nCounter analysis are shown in Appendix 
6.2. To process the data, the counts were first normalized with respect to the 
geometric mean of the positive control counts using the nSolver software program 
provided by Nanostring nCounter. In a second step, the counts were normalized 
with respect to the geometric mean of ornithine decarboxylase (ODC). Even though 
additional housekeeping genes were present in the Nanostring set, only ODC was 
chosen for normalization as the other genes show developmental regulatory 
effects. Finally, a stringent background correction was performed by subtracting the 
mean and two standard deviations of the eight negative control counts for each 
lane. Values less than 1 were set to 1 as background level. Two independent 









3.1 Temporally controlled modulation of canonical Wnt signaling activity 
in Xenopus embryos 
 
Wnt/β-Catenin signalinghas been shown to play important roles during 
embryonic development and deregulation of thissignalingpathway has been 
implicated in tumor development. In order to study the function of canonical Wnt 
signaling during specific developmental processes, tools have to be developed 
that modulate canonical Wnt signaling activity under tight temporal control. For 
this issue, we wanted to generate hormone-inducible constructs that have the 
potential to either stimulate or repress canonical Wnt signaling activity in 
Xenopus embryos. We used modified versions of the transcriptional coactivator 
β-Catenin and the transcription factors Tcf3 and Lef1 (Figure 9 A-C). Wildtype 
β-Catenin protein contains an amino-terminal domain that is responsible for 
protein instability.Mutation of the serine residue 33 in the N-terminal domain of 
β-Catenin results in a stabilized protein that is no longer vulnerable to initial 
phosphorylations leading to β-Catenin destruction(Aberle et al., 1997; Morin et 
al., 1997).This stabilized form of β-Catenin was further modified by substitution 
of the trans-activation domain with either the Herpes simplex virus VP16 
transcriptional activation domain (VP16) or the Drosophila melanogaster 
Engrailed repression domain (EnR), resulting in the predicted constitutively 
active and dominant negative versions of β-Catenin (Figure 9 
A).Trancriptionfactors of the Lef/Tcf family have a similar organization regarding 
their protein domain structure. These proteins contain an amino-terminal β-
Catenin binding domain, a central domain for groucho/TLE interaction, a DNA 
binding HMG box, and a C-terminal tail (Figure 9 B, C). We used an amino-
terminal deletion mutant of Tcf3 that is predicted to interact with β-Catenin, 
while still binding to the target DNA sequence and masking it from binding to 
other transcriptional activating complexes (Molenaar et al., 1996).Additionally, 
another Tcf3 deletion mutant lacking the HMG DNA binding domain was 





interaction with endogenous transcription factors (Figure 9 B). Tcf3∆C is a 
mutant version of Tcf3 lacking the C-terminal domain that is important for CtBP 
binding. CtBP is a transcriptional co-repressor that mediates histone 
modification(Shi et al., 2003). However, this mutant had previously been shown 




Figure 9. Schematic representation of GR-fusion constructsemployed for 
modulation of Wnt signaling. (A) Overview of wildtype and modified versions of 
human  β-Catenin. Mutations in the nucleotide sequence leading to a single amino acid 
exchange and stabilization of mutant β-Catenin are indicated. (B) Scheme of Xenopus 
Tcf3 and corresponding GR-fused deletion mutants of XTcf3. (C) Overview of GR-
fused wildtype or mutant versions of mouse Lef1. (A-C) Mutant versions of β-Catenin, 
Tcf3, and Lef1 lacking specific protein domains or chimeric constructs containing 
endogenous protein domains and VP16 transcriptional activation or EnR transcriptional 
repression domain. All construct were fused to the human GR ligand binding domain. 





depicted factors concerning modulation of canonical Wnt signaling are specified: pos, 
positive regulation; neg, negative regulation.  
 
Behrens and colleagues had shown that the full-length transcription factor Lef1 
induces secondary axis formation upon ventral overexpression in Xenopus 
embryos (Behrens et al., 1996). Therefore, this construct was used as canonical 
Wnt signaling stimulating factor in this study (Figure 9 C). In addition a deletion 
mutant of Lef1 lacking the β-Catenin binding domain was included into our set 
of putative canonical Wnt signaling regulating factors (Figure 9 C). 
To gain temporal control of protein activity, one can make use of fusion proteins 
that contain the ligand binding domain (LBD) of steroid-hormone receptors, 
such as the glucocorticoid receptor (GR). GR-fusion proteins are bound and 
inactivated by heat shock proteins in the cytoplasm immediately after 
translation. To induce protein activity, cells are treated with the steroid hormone 
Dexamethasone (DEX), which binds the GR-LBD and causes a release 
fromheat shock proteins. Consequently, the activated GR-fusion protein can 
translocate to the nucleus and modulate target gene transcription.All constructs, 
described above, were fused to the hormone-inducible GR-LBD (Figure 9 A-C). 
Apart from the factors described above, we included2additional GR-fusion 
constructs that had already been described to modulate canonical Wnt signaling 
activity dependent on DEX treatment. EnR-Lef1-GR consists of the Drosophila 
Engrailed repression domain and the mouse Lef1-DNA binding domain fused to 
the human GR-LBD and acts as repressor of canonical Wnt signaling activity 
(Lyons et al., 2009). In contrast, LefΔN-VP16-GR containing mouse Lef1-DNA 
binding domain, the VP16 transcriptional activation domain, and GR-LBD, was 
shown to activate Wnt/β-Catenin signaling(Denayer et al., 2008). 
Formation of the dorsal-ventral body axis in Xenopus embryos is initiated via 
high levels of nuclear β-Catenin in the dorsal endoderm of early cleavage stage 
embryos.As a result, the Spemann organizer is induced in the dorsal mesoderm 
and allows the development of dorsal structures. Ectopic activation of Wnt 
signaling on the ventral side induces the formation of a secondary body axis. 
This system was used to test Wntsignalingpromoting activities and hormone 
inducibilitiy of the generated GR-fusion constructsdescribed above.mRNAs 
coding for predicted canonical Wnt signaling stimulating factors were injected 





treated with DEX  to induce protein activity. At late tailbud stages embryos were 
scored for secondary axis formation (Figure 10 A). All those factors that were 
predicted to stimulate canonical Wnt signaling efficiently induced secondary 
axis formation upon treatment with DEX (Figure 10 C, D; Table 7). Full-length 
Lef∆N-VP16-GR and Lef1-GR induced canonical Wnt signaling activity upon 
DEX-mediated activation (Figure 10 C; Table 7). In contrast, GR-fused mutant 
versions of β-Catenin showed secondary axis induction also in the absence of 
DEX (Figure 10 D, Table 7). 
 
 
Figure 10. GR-fusion constructs were tested for canonical Wnt signaling 
modulating activity and DEX-inducibility using axis duplication or ventralization 
assay. (A) Xenopus embryos were injected into the marginal zone of one ventral 
blastomere, DEX-treated until early tailbud stages and scored for the formation of a 
secondary body axis (C-D). (B) Xenopus embryos were injected into the marginal zone 





ventralized phenotype (E-F). (C-F) Embryos were injected with different amounts of 
LefΔN-VP16-GR, Tcf3∆C-GR, βcatS33A∆TA-VP16-GR, or Tcf∆HMG-GR mRNA and 
treated with DEX as inicated. (C-D) Lef1-GR and βcatS33A∆TA-VP16-GR both 
stimulate secondary axis formation. (C) LefΔN-VP16-GR activity is DEX-dependent. (D) 
βcatS33A∆TA-VP16-GR-mediated secondary axis induction occurs independently of 
DEX-treatment. (E-F) Ventral overexpression of Tcf3∆C-GR and Tcf∆HMG-GR results 
in the development of reduced dorso-anterior structures. (E) Tcf3∆C-GR-mediated 
ventralization is strongly enhanced by DEX-treatment. (F) Tcf∆HMG-GR strongly 
induces ventralization phenotype independently of DEX.  
 
Dorsal inhibition of Wnt/β-Catenin signaling in Xenopus embryos suppresses 
the induction of the Spemann organizer and results in the formation of a 
ventralized phenotype. These embryos show reduced dorso-anterior structures, 
like cement gland and eye anlage (Figure 10B). In order to analyze activity and 
inducibility of predicted canonical Wnt signaling repressing GR-fusion 
constructs, mRNAs coding for these factors were injected marginally into both 
dorsal blastomeres of 4-cell stage embryos.Injected embryos were treated with 
DEX and cultivated until late tailbud stages for ventralization phenotype analysis 
(Figure 10 B). All of these dorsally expressed GR-fusion constructs induced 
ventralization even without DEX treatment (Figure 10 E, F; Table 7). However, 
TCF3ΔC-GR and EnR-Lef1-GR repress canonical Wnt signaling in a dose-
dependent manner and protein activity was enhanced by addition of DEX 
(Figure 10 E; Table 7). 
To confirm the data gained from axis duplication and ventralization assays, we 
tested signaling activity and inducibility of GR-fusion constructs in the Xenopus 
animal cap system.Stimulation or repression of canonical Wnt signaling can be 
monitored by expression analysis of direct Wnt/β-Catenin target genes, such as 
Nodal-related 3 (Xnr3) or Siamois(Ghogomu et al., 2006).Embryos were 
injected animally with mRNAs coding for GR-fusion proteins and treated with 
DEX immediately after injection. At blastula stage, animal ectodermal tissue 
was dissected and cultivated until mid-gastrula stage for target gene expression 
analysis, using RT-PCR (Figure 11 A).Consistent with the data from axis 
duplication assays, Wnt/β-Catenin target gene expression is induced by Lef1-
GR and βcatS33AΔTA-VP16-GR. While Lef1-GR activity is induced by DEX, 
βcatS33AΔTA-VP16-GR promotes expression of Xnr3 and siamois DEX-
independently (Figure 11 B, D; Table 7). In order to analyze activity of Wnt/β-





coexpressed with canonical Wnt signaling stimulating factors, such as 
Dishevelled (Dvl) or β-Catenin (Figure 11 C, D).Tcf3ΔHMG-GR inhibited Dvl-
mediated target gene expression. However, as observed in the ventralization 
assay, Tcf3ΔHMG-GR activity was not induced by DEX (Figure 11 C; Table 7). 
Surprisingly, 2 GR-fusion proteins, namely LefΔBD-GR and βcatS33AΔTA-EnR-
GR, that were predicted to repress canonical Wnt signaling activity, were found 
to induce secondary axis formation and β-Catenin target gene expression 
(Figure 11 D; Table 7). 
 
 
Figure 11. Activity and DEX-inducibilty of GR-fusion constructs as tested by 
gene expression analysis in animal cap explants.(A-D) Xenopus embryos were 
injected animally into both blastomeres at 2-cell-stage, ectodermal animal cap tissue 
was dissected at stage 8 and treated with Dexamethasone (DEX) until stage 11, when 
ectodermal explants were fixed for RT-PCR analysis. (B-D) Embryos were injected with 
50 pg, 100 pg, or 150 pg Lef1-GR, 200 pg MT-Dsh, 50 pg or 100 pg TCF3-AΔHMG-
GR, 400 pg β-Catenin, 25 pg βcatS33AΔTA-EnR-GR, 25 pg βcatS33AΔTA-VP16-GR 
mRNA and treated with Dexamethasone, as indicated. RNA extracts were analysed for 
expression of Xnr3 (B-C) and Siamois (D). RT-PCR for histone H4 was included as 





dependently upon activation with DEX. (C) TCF3-AΔHMG-GR inhibits MT-Dsh-
mediated target gene expression independently of DEX-treatment. (D) βcatS33AΔTA-
EnR-GR and βcatS33AΔTA-VP16-GR both induce canonical Wnt target gene 
expression in the absence of DEX. CE – uninjected control embryo; CC – control 
animal cap tissue from uninjected embryos. 
 
In summary,we have identified constructs that either inhibit or induce canonical 
Wnt signalingin a DEX dependent manner; these are: Lef1-GR and LefΔN-
VP16-GR (activators) as well as TCF3ΔC-GR and EnR-Lef1-GR (repressors). 
 
Table 7.Summary of canonical Wnt signaling modulating activity and DEX inducibility 
of GR-fusion constructs used in this study. 
GR-fusion construct 
axis phenotype Target gene expression DEX 
inducibility axis 
duplication ventralization activation repression 
βcatS33A-GR yes n.d. n.d. n.d. no 
GR-βcatS33Y yes n.d. n.d. n.d. no 
βcatS33AΔTA-VP16-GR yes n.d. n.d. n.d. no 
Lef1-GR yes n.d. yes no yes 
LefΔN-VP16-GR yes n.d. yes n.d. yes 
LefΔBD-GR yes yes yes yes yes 
TCF3ΔC-GR n.d. yes n.d. n.d. yes* 
EnR-Lef1-GR n.d. yes n.d. n.d. yes* 
βcatS33AΔTA-EnR-GR yes yes n.d. n.d. no 
GR-Tcf3ΔN n.d. yes n.d. n.d. no 
GR-Tcf3ΔHMG n.d. yes n.d. n.d. no 
Tcf3ΔHMG-GR n.d. yes n.d. yes no 
GSK3β-GR n.d. yes n.d. n.d. no 
GR-fusion constructs with confirmed signaling activity and inducibility are highlighted in purple. 
yes* indicates that DEX did not induce but enhance activity of the corresponding GR-fusion proteins.  
 
3.2 Modulation of canonical Wnt signaling activity interferes with 
pancreas specification and differentiation 
 
Previous studies in Xenopus as well as in other model systems had shown that 
canonical Wnt signaling plays important roles during patterning of the primitive 
gut tube, including aspects of specification, differentiation, and proliferation of 





endodermal organ development have been proposed. While McLin and 
colleaguesdiscuss an anterior-posterior gradient of canonical Wnt 
signalingactivity within the gut tube, other studies suggested a model that is 
defined by temporal modulations β-Catenin stability in respect to the 
corresponding developmental phase(Damianitsch et al., 2009; Dessimoz et al., 
2005; Heiser et al., 2006; McLin et al., 2007; Murtaugh et al., 2005).  
In order to analyze the role of canonical Wnt signaling during pancreatic 
development, mRNAs coding for inducible canonical Wnt signaling activating or 
repressing GR-fusion proteins were injected into the vegetal pole of all 4 
blastomeres of stage 3 Xenopus embryos. Embryos were treated with DEX 
either at stage 12, before the pancreatic anlage is specified, or at stage 30, 
when pancreatic specification is completed, and cultivated until stage 40(Figure 
12 A). Embryos were analyzed for expression of pancreatic protein disulfide 
isomerase (PDIp), which is an earlymarker for differentiation of the exocrine 
pancreatic cell lineage(Afelik et al., 2004).In the control situation, PDIp 
transcripts are detected strongly in the dorsal and ventral pancreatic bud and 
PDIp expression is not altered by DEX treatment (Figure 12 B,C). 
As shown earlier, embryos injected with Lef1-GR are devoid of the dorsal 
pancreas both after early and late activation of the GR-fusion protein (Melchert, 
2007). However, LefΔN-VP16-GR had no effect on PDIp expression (Figure 12 
C). Early and late repression of canonical Wnt signaling using microinjection of 
Tcf3ΔC-GR mRNA caused the loss of both ventral and dorsal pancreatic 
anlage. However, a similar phenotype was observed for embryos that were not 
treated with DEX (Figure 12 B, C). Therefore, reduced XPDIp expression in the 
dorsal and ventral pancreas upon Tcf3ΔC-GR expression might also be a 
secondary effect caused by an impairment of earlier developmental events. 
However, this result is consistent with data from ventralization assays showing 
that Tcf3ΔC-GR is active even in the absence of DEX (Figure 10 E; Table 7). 
While early repression of Wnt/β-Catenin signaling using EnR-Lef1-GR caused 
reduced expression of PDIp in the dorsal pancreas, activation of the protein at 
stage 30 did not interefere with exocrine pancreatic development (Figure 12 B, 
C), (Forchmann, 2009). Furthermore, transcript levels of Insulin that is 
specifically expressed in the endocrine β-cells were neither early nor late altered 





These data show that both repression and hyperactivation of canonical Wnt 
signaling before and after specification of the dorsal pancreatic anlage can 
result in impaired exocrine pancreatic development. In contrast, development of 
the ventral pancreas was not influenced by increased Wnt/β-catenin signaling. 
However, based on these data we cannot definitively conclude a requirement 
for Wnt signaling activity in the context of ventral pancreatic development. 
 
 
Figure 12. Stimulation and Inhibition of canonical Wnt signaling before and after 
pancreatic specification result in a reduced expression of the exocrine 
pancreatic marker XPDIp. (A) Xenopus embryos were injected into the vegetal pole of 
all 4 blastomeres at the 4-cell stage and cultivated either until stage 12 or stage 30 for 
Dexamethasone (DEX) treatment until stage 40. (B) Shown are representative 
embryos exhibiting either normal XPDIp expression (left panel) or reduced XPDIp 
expression only in the dorsal (↓) or in both dorsal and ventral (↓↓) pancreatic anlage. 
XPDIp expression was determined using WMISH. Black arrow heads indicate reduced 
dorsal pancreas; white arrow head indicates reduced ventral pancreas. (C) Summary 
of phenotypes in the context of XPDIp expression observed upon activation (Lef1-GR, 
Lef∆N-VP16-GR) or repression (Tcf3∆C-GR,EnR-Lef1-GR) of canonical Wnt signaling. 
Embryos were injected with 75 pg Lef1-GR, 300 pg Lef∆N-VP16-GR, 100 pg Tcf3∆C-
GR, or 500 pg EnR-Lef1-GR mRNA and treated with DEX at stage 12 or at stage 30, 
as indicated. XPDIp expression was analyzed using WMISH and 2 phenotypes were 
observed: ↓ reduced dorsal pancreas; ↓↓ reduced ventral and dorsal pancreas. 
Percentages of embryos showing the corresponding phenotype and numbers of 





from Melchert, 2007; data shown for EnR-Lef1-GR injected embryos are taken from 
Forchmann, 2009. 
 
3.3 Ectopic Fam132b induces formation of a secondary body axis in 
Xenopus embryos 
 
To identify novel regulators of Wnt/β-Catenin signaling, expression cloning was 
carried out, using primary body axis formation in Xenopus embryos as a read 
out system. A Xenopus tropicalis full-length cDNA library, containing more than 
9000 individual cloneswas used(Gilchrist et al., 2004).  
 
 
Figure 13. Schematic illustration of expression cloning. Bacteria containing 





extraction cDNA clones were PCR amplified and pooled within rows. After in vitro 
synthesis, 1.6 ng of mRNA  pools were injected animally into both blastomeres of 2-
cell-stage Xenopus laevis embryos. Embryos were cultivated  until stage 30 for 
phenotype analysis. 
 
cDNA clones were amplified by PCR and pools of 24 cDNA clones each were 
transcribed  in vitro(kindly provided by K. Henningfeld). Xenopus laevis embryos 
were injected with these pools of mRNAs animally into bothblastomeres at the 
2-cell-stage and analyzed for axis formation defects at early tadpole stages 
(Figure 13). Embryos expressing one of these mRNA poolsexhibited a 
dorsalized phenotype (Figure 14 A).  
 
 
Figure 14. Expression cloning identifies Fam132b a dorsalizing factor. (A-K) 
Hierarchy of injected mRNA pools and observed phenotypes. mRNA mixtures derived 
from pools of X. tropicalis full-length cDNA clones were injected into both blastomeres 
at the 2-cell-stage. Embryos were cultivated to tailbud stage and screened for axis 
formation. 1.6 ng (A), 800 pg (B, C), 500 pg (D, E) or 120 pg (F-K) of total mRNA were 
injected per embryo. Numbers of individual clones per injected mRNA pool are 





Percentages of embryos exhibiting the shown phenotype in respect to the whole 
number of analyzed embryos is shown in the lower right hand corner of each panel. 
 
This phenotype is defined by overrepresentation of very anterior structures, 
such as the cement gland, as well as by a shortened body axis (Figure 14 A, C, 
E, I). In order to identify the active clone, the dorsalization-positive pool was 
subdivided into pools of 12, followed by subdivision into pools of 6individual 
clones. These mRNA pools were microinjected and embryos were analyzed, as 
described above (Figure 14 B-E). Ectopic expression of the 6 remaining 
individual clones lead to the identification of one clone as inducer of the 
observed dorsalized phenotype (Figure 14 F-K). Thisclone TTpA078f11 could 
be assigned to Xenopus tropicalisFam132b (AN: NM_001078919). 
 
 
Figure 15. Fam132b induces secondary axis formation upon ventral 
overexpression.(A) Xenopus embryos were injected at the four-cell stage into the 
marginal zone of one ventral blastomere and cultivated until stage 28 for phenotype 
analysis. VMZ – ventral marginal zone. (B-E) Fam132b induces secondary axis 
formation. (B-D) Representative embryos showing partial or complete secondary axis 
formation and corresponding as indicated. Embryos are depicted in a lateral view with 
anterior to the left (B), in a lateral view with anterior to the top (C) or in a dorsal view 
with anterior to the left (D). Black arrows indicate the anterior tip of a complete body 
axis; white arrow head marks the anterior tip of a partial secondary body axis. (E) 
Quantification of embryos showing partial or complete secondary axis formation after 
ventral overexpression of increasing amounts of Fam132b, as indicated. 30 pg, 60 pg, 





A dorsalized phenotype similar to that observed after expression of Fam132b 
mRNA could be caused by activation of Wnt/β-Catenin signalingbut also by 
inhibition of BMP signaling in the early embryo(Oelgeschlager et al., 2003; 
Williams et al., 2005). Modulations of these signaling pathways, if restricted to 
the ventral marginal zone of the embryo, can induce secondary axis formation 
inXenopus embryos(Fagotto et al., 1997; Funayama et al., 1995; Graff et al., 
1994; Suzuki et al., 1994). 
To determine if Fam132b can induce axis duplication as well, Fam132b mRNA 
was injected marginally into 1 ventral blastomere at the 4-cell-stage. Indeed, 
Fam132b shows predominantly partial secondary axis inducing activity (Figure 
15 A-C).These data suggest that Fam132b might be a protein with the potential 
to either stimulate Wnt/β-Catenin signaling or negatively regulate BMP 
signaling. 
 
3.4 Fam132b does not activate Wnt/β-Catenin signaling 
 
Since Fam132b exhibits secondary axis inducing activity, we asked ifFam132b 
could act as a Wnt/β-Catenin signaling stimulating factor. For this purpose, 
Fam132b activity was analyzed in the Xenopus animal cap assay. Fam132b 
mRNA was injected into both blastomeres of 2-cell-stage embryos. At blastula 
stage animal ectodermal tissue (animal cap) was explanted and cultivated until 
sibling control embryos had reached gastrula stage.Animal caps, which do not 
show Wnt/β-Catenin signaling activity, were analyzed for direct canonical target 
gene expression using RT-PCR (Figure 16 A). While Wnt8 strongly activates 
the expression of Xnr3, transcriptional induction of Xnr3 was not observed upon 
ectopic Fam132b expression (Figure 16B). 
Furthermore, Fam132b activity was analyzed in the luciferase assay using a 
Wnt-responsive Siamois reporter construct. The siamois reporter construct, 
which contains the firefly luciferase gene under control of the siamois promoter, 
was injected together with a Renilla reporter construct into both blastomeres of 
a 2-cell-stage embryo (Brannon et al., 1997). Since Renilla reporter gene 
activation is independent of Wnt signaling activity, this construct was used for 





gastrula stage and analyzed for luciferase activity. While expression of Wnt8 
mRNA dramatically increased Siamois reporter gene activity in the embryo, 
ectopic expression of Fam132b did not influence the level of endogenous 
canonical Wnt signaling (Figure 16 A, C). 
To answer the question, if Fam132b might act as a Wnt/β-Catenin 
signalingenhancing factor, Fam132b was coexpressed together with decreasing 
doses of Wnt8 mRNA in the ectodermal animal cap tissue, as described above. 
RT-PCR analysis revealed that Fam132b does not increase Wnt8 induced Xnr3 
expression (Figure 16 A, D). Hence, a synergistic activity between Fam132b 
and Wnt8 can be excluded. 
 
 
Figure 16. Overexpression of Fam132b does not modulate endogenous or 
ectopicaly activated canonical Wnt signaling activity. (A) Xenopus embryos were 
injected into both blastomeres at the 2-cell stage and cultivated either until stage 11 for 
luciferase assay or until stage 8 for dissection of the animal cap tissue. Ectodermal 
explants were cultivated until stage 11 and analyzed using RT-PCR. (B) Fam132b 
does not induce transcription of Xnr3 in animal cap cells. 30 pg MT-Wnt8, 250 pg tBR 
and 30 pg, 60 pg or 120 pg of XtFam132b mRNA were injected per embryo. (C) 





pg XtFam132b, and 250 pg tBR mRNA were injected per embryo and 3 samples 
containing 15 embryos each were analyzed. The graphs show the summary of 2 
independent experiments; standard errors are indicated. Siamois-Luc reporter gene 
activity was normalized to Renilla reporter gene activity. Siamois-Luc reporter gene 
activity, induced by endogenous Wnt/β-Catenin signaling, was set to 1. (D) MT-Wnt8-
mediated induction of Xnr3 transcription in animal cap explants is not enhanced by 
Fam132b coexpression. 40 pg, 4 pg or 0.4 pg MT-Wnt 8 and 120 pg XtFam132b 
mRNA were injected per embryo, as indicated. 
 
In addition, expression of Fam132b in the axis duplication assay resulted in the 
formation of predominantly partial secondary body axis, lacking the very anterior 
structures, like cement gland or eye anlage (Figure 15). In contrast, ventral 
overexpression of Wnt/β-Catenin signaling activating factors, such as Wnt8, 
induce the formation of complete secondary axis, exhibiting those anterior 
structures(Fagotto et al., 1997; Funayama et al., 1995). Taken together, these 
data show that ectopic Fam132b neither activates norenhances canonical Wnt 
signaling activity in Xenopus embryos. 
 
3.5 BMP signaling activity is repressed by ectopic Fam132b expression 
 
Apart from activation of canonical Wnt signaling, ventral inhibition of BMP 
signaling can induce secondary axis formation in Xenopus embryos(Graff et al., 
1994; Suzuki et al., 1994). Therefore, we asked if Fam132b exhibits BMP 
antagonizing activity. To answer this question, we ectopically expressed 
Fam132b in animal cap cells, where BMP signaling is active. Xenopus embryos 
were injected with mRNA coding for Fam132b animally into both blastomeres at 
the 2-cell stage and animal caps were dissected at blastula stage (Figure 17 
A).RT-PCR analysis of gastrula stage ectodermal explants revealed that 
transcriptional levels of direct BMP target genes, such as Vent1/2 or Msx1/2 are 
downregulated upon Fam132b expression, as observed for animal cap explants 
expressing the dominant negative truncated BMP receptor (tBR) or the secreted 
BMP antagonist Noggin (Figure17C). It has been shown, that repression of 
BMP signaling activity induces neural differentiation in embryonic ectodermal 
explants (Lamb et al., 1993; Sasai et al., 1995). Correspondingly, we found the 
neural cell adhesion molecule (N-CAM) to be upregulated in Fam132b 







Figure 17. Overexpression of Fam132b antagonizes BMP-mediated target gene 
transcription (A) Both blastomeres of 2-cell-stage Xenopus embryos were injected 
animally, ectodermal animal cap tissue was dissected at stage 8 und cultivated until 
stage 12 for RT-PCR analysis. (B) Xenopus embryos were injected marginally into both 
ventral blastomeres at the 4-cell stage, ventral mesodermal tissue was explanted at 
stage 10.25 and cultivated until stage 12 for RT-PCR analysis. (C) Overexpression of 
Fam132b inhibits BMP target gene (Vent1/2, Msx1/2) expression and stimulates 
expression of the neural marker N-CAM in animal cap explants. (D)  BMP target gene 
transcription is downregulated and expression of secreted BMP antagonists is 
stimulated upon overexpression of Fam132b in ventral mesodermal explants. (C-D) 
300 pg tBR, 100 pg Noggin, 100 pg and 200 pg (C) or 250 pg and 500 pg (D) 
XtFam132b mRNA was injected per embryo, as indicated. RT-PCR for histone H4 was 
included as loading control. Overexpression of tBR and Noggin was included as control 
for BMP antagonizing activity. CE – uninjected control embryo; CC – control animal cap 
tissue from uninjected embryos; CVM – control ventral mesoderm from uninjected 
embryos. 
 
Furthermore, we analyzed Fam132b activity in ventral mesodermal explants 
that highly express direct BMP target genes. For this pupose, Fam132b mRNA 
was injected marginally into both ventral blastomeres of 4-cell-stage Xenopus 
embryos. Ventral mesoderm was explanted at stage 10.25 and cultivated until 





cap system, Fam132b as well as Noggin inhibits BMP target gene expression in 
ventral mesodermal explants (Fig 17 D). However, expression of tBR did not 
affect expression of Vent2 and Msx2.Inhibition of BMP signaling can induce the 
expression of organizer specific genes in the ventral mesoderm (Dosch and 
Niehrs, 2000). Similarly, Fam132b induces transcriptional activation of the 
organizer genes Noggin, Chordin, and Follistatin(Agius et al., 2000; Yamamoto 
et al., 2000), as observed previously upon expression of tBR (Figure 17 D). 
 
 
Figure 18. Fam132b represses BMP4- and BMP2-mediated BMP signaling 
activity. (A) Xenopus embryos were injected into both dorsal blastomeres at the 4-cell 
stage and cultivated either until stage 11 for luciferase assay or until stage 28 for 
phenotype analysis. (B) Coexpression of XtFam132b rescues the BMP4 induced 
ventralization phenotype. 1 ng BMP4 and 100 pg XtFam132b mRNA were injected per 
embryo, as indicated. (C) XtFam132b represses BMP4- and BMP2 stimulated Vent2b-
BRE-Luc reporter gene activity. 1 ng BMP4, 1 ng BMP2, and 100 pg XtFam132b 
mRNA were injected per embryo and 3 samples containing 15 embryos each were 
analyzed per experiment. The graphs show the summary of 2 independent 
experiments; standard errors are inicated. Vent2b-BRE-Luc reporter gene activity was 
normalized to Renilla reporter gene activity. Vent2b-BRE-Luc reporter gene activity, 
induced by endogenous BMP signaling was set to 1. 
 
The RT-PCR experiments described above have shown that Fam132b inhibits 





antagonize ectopic BMP signaling, Fam123b mRNA was injected together with 
mRNA coding for BMP4 marginally into both dorsal blastomeres of 4-cell-stage 
embryos. These embryos were cultivated until late tailbud stages for phenotype 
analysis (Figure 18 A). While expression of BMP4 by itself induces strong 
ventralization of Xenopus embryos, Fam132b expression results in the 
formation of a dorsalized phenotype, as described above. Coexpression of 
Fam132b together with BMP4 could partially rescue BMP4-mediated 
ventralization (Figure 18 B). 
Additionally, Fam132b activity was analyzed using the luciferase reporter assay. 
The Vent2b-BRE-Luc reporter construct(Henningfeld et al., 2000), containing 
the Firefly luciferase gene under control of the BMP responsive minimal Vent2b 
promoter, was injected together with the Renilla reporter construct into the 
dorsal marginal zone of 4-cell stage embryos. Embryos were cultivated until 
gastrula stage and analyzed for luciferase activity (Figure 18 A). Endogenous 
BMP signaling activity is relatively low in the dorsal embryo, but reporter gene 
activity is significantly upregulated by overexpression of BMP2 and BMP4 
mRNAs. Fam132b coexpression inhibits both, endogenous as well as BMP2- 
and BMP4-mediated reporter gene activation (Figure 18 C). These data indicate 
that Fam132b antagonizes BMP signaling activity. 
 
3.6 Fam132b selectively inhibits BMP signaling 
 
Activity of the TGF-β family of signalingpathways is tightly regulated during 
development and tissue homeostasis. Several factors are known to antagonize 
BMP, activin or Nodalsignaling. Some inhibitors are specific for the BMP 
signaling pathway, such as Noggin or Chordin(Sasai et al., 1994; Smith and 
Harland, 1992),while others antagonize more than one signaling pathway. BMP-
3, Follistatin, or BAMBI were shown to antagonize activin as well as BMP signal 
transduction pathways(Fainsod et al., 1997; Gamer et al., 2005; Hemmati-
Brivanlou et al., 1994; Onichtchouk et al., 1999). To elucidate if Fam132b is a 
BMP-specific inhibitor, we analyzed the effect of Fam132b on either eFGF-, 
activin, or BMP4 induced target gene expression. All these signaling molecules 





finger transcription factor Early growth response protein 1 (egr-1) upon 
overexpression in animal cap explants(Panitz et al., 1998). Embryos were 
injected into both blastomeres at the 2-cell stage and cultivated until blastula 
stage for dissection of animal ectodermal tissue(Figure19 A). RT-PCR analysis 
reveals that target gene transcription induced via eFGF or activin signaling is 
not influenced by Fam132b, while BMP4-mediated target gene induction is 
completely repressed upon coexpression of Fam132b (Figure19B).These 
results suggest that the antagonizing activity of Fam132b is specific for the 
BMP-mediated signaling pathway. 
 
 
Figure 19. Fam132b selectively antagonizes BMP induced target gene 
transcription(A) Xenopus embryos were injected animally into both blastomeres at the 
2-cell-stage, ectodermal animal cap tissue was dissected at stage 8 und cultivated until 
stage 12 for RT-PCR analysis. (B)  Fam132b interferes with BMP-induced target gene 
expression, while eFGF- and activin-mediated transcriptional induction is not influenced 
by Fam132b. 10 pg eFGF, 1 pg activin, 1 ng BMP4, and 100 pg XtFam132b mRNAs 
were injected per embryo, as indicated, and RNA extracts were analyzed for Xbra and 
egr-1 expression. RT-PCR for histone H4 was included as loading control. CE – 









3.7 The BMP antagonizing activity of Fam132b is mediated on the 
extracellular level 
 
BMP signaling activity isregulated by multiple mechanisms, including 
intracellular and extracellular antagonism.Analysis of the predicted Xenopus 
tropicalis Fam132b protein sequence using SMART (Simple Modular 
Architecture Research Tool) reveals that it contains an N-terminal signal peptide 
of 33 amino acids, suggesting that this protein is a secreted factor 
(http://smart.embl-heidelberg.de/). To test this hypothesis hemagglutinin epitope 
(HA)-tagged Fam132b mRNA was injected vegetally into stage VI Xenopus 
laevis oocytes. Oocytes were cultivated for 24 hours, followed by Western Blot 




Figure 20. Fam132b is a secreted protein. (A) Stage VI oocytes were injected  into 
the vegetal pole and cultivated for 24 hours. Oocytes  (Oo) and Oocyte Culture Medium  
(OCM) were separated and protein extracts were prepared. (B) Fam132b-HA protein is 
secreted upon overexpression in Xenopus oocytes. 100 pg Su(H)-HA was coinjected 
with either 150 pg Fam132b-HA or 150 pg sFRP5-HA mRNA. Su(H) and sFRP5 served 
as controls for non-secreted and secreted proteins, respectively. The expression of HA-
tagged proteins was analyzed by Western Blot.  
 
An HA-fused version of the transcription factor Suppressor of Hairless (Su(H)) 
was coexpressed as internal control for non-secreted proteins. Within one day 





tagged proteins. As expected, Su(H)-HA protein was exclusively detected in the 
oocyte fraction, while the known secreted factor sFRP5-HA was found in the 
OCM  (Figure20 B). Consistent with the finding that the Fam132b protein 
contains a signal peptide sequence, Fam132b-HA protein was similarly 
detected in the OCM, while being absent from the oocyte fraction (Figure20 B). 
These data indicate that Fam132b is a secreted factor, raising the possibility 




Figure 21. Fam132b inhibits BMP signaling activity on the extracellular level.  (A) 
Xenopus embryos were injected at the 4-cell stage into the marginal zone of both 
dorsal blastomeres and cultivated until stage 11 for luciferase assay. DMZ – dorsal 
marginal zone. (B) Fam132b does not inhibit caBMPR induced reporter gene 
activation. The graphs summarize the results of three independent experiments; 
standard errors are indicated. Three samples containing 15 embryos each were 
analysed per experiment. 1 ng caBMPR, 1 ng BMP4 and 200 pg Fam132b mRNA per 
embryo were injected. Vent2b-BRE-Luc reporter gene activity was normalized to 
Renilla reporter gene activity. Vent2b-BRE-Luc Reporter gene activity induced by 
endogenous BMP signaling was set to 1. 
 
To experimentally test this assumption, Fam132b was coexpressedwith either 
the constitutively active BMP receptor (caBMPR) or BMP4. Fam132b activity 





construct Vent2b-BRE-Luc (Henningfeld et al., 2000)and the BMP signaling 
independent Renilla luciferase reporter, as described above (Figure21 A, B). 
The caBMPR is a BMP type I receptor containing a mutation in the intracellular 
domain and it stimulates BMP signaling activity independently of the BMP 
protein(Candia et al., 1997). Reporter gene activity that is induced by caBMPR 
is antagonized exclusively by factors that function downstream of the receptor. 
As shown above, Fam132b efficiently inhibits reporter gene activity that was 
induced by BMP4, while caBMPR-stimulated reporter gene activity is not 
significantly affected (Figure21 B). These results show that the secreted protein 
Fam132b antagonizes BMP signaling activity on or upstream of the receptor 
level.  
 
3.8 Fam132b physically interacts with BMP specific type I receptors 
 
Previous studies identified a family of BMP antagonists, containing Noggin and 
Chordin,that function via direct binging to the BMP proteins and thereby 
blocking the interaction of BMPs with their receptors(Piccolo et al., 1996; 
Zimmerman et al., 1996). To investigate if Fam132b is a member of this family 
of BMP antagonistsco-immunoprecipitation (CoIP) experiments with Fam132b 
and BMP4 in Xenopus embryos were carried out. CoIP analysis using Noggin 
and BMP4 served as positive control. mRNAs coding for epitope-tagged 
versions of Fam132b, Noggin, and BMP4 were injected at the 2-cell stage and 
embryos were cultivated until gastrulation (Figure 22 A). Embryonic lysates 
were subjected to CoIP analysis using antibodies against the HAepitope-tag. As 
expected, Noggin-MT strongly interacts with BMP4-HA.CoIP of BMP4-HA 
andFam132b-MT-GR reveals that there is significant albeit weak binding 
between these proteins (Figure22 A, B). 
Unlike BMP antagonists that regulate BMP availability, other factors, such as 
inhibin and BMP-3, have been identified as BMP receptor inhibitors(Gamer et 
al., 2005; Wiater and Vale, 2003). To test, if Fam132b interacts with BMP 
receptors, CoIP experiments between epitope-tagged versions of the BMP-
specific type I receptors Alk2 or Alk3 and Fam132b were carried out (Figure 22 





Alk3 (Figure22 C), but not with the human TGFβ type I receptor Alk4-HA, which 
is specific for TGF-β ligands different from BMP proteins (data not 
shown),These data suggest that Fam132b antagonizes BMP signaling activity 
primarily via receptor binding.The direct binding to the BMP protein described 




Figure 22. Fam132b strongly interacts with BMP type I receptors, and weakly 
with BMP4. (A) Xenopus embryos were injected animally into both cells at the 2-cell 
stage and lysed at stage 11 for CoIP using anti-HA antibody (B) or anti-MT antibody 
(C). (B-C) CoIP experiments showing Xenopus lysates used for CoIP in the left panels 
and precipitated or co-precipitated proteins in the right panels. Embryo lysates and 
CoIP samples were analyzed by Western Blot using  anti-HA and anti-MT antibodies, 
as indicated. (B) Fam132b-MT-GR weakly co-precipitates with BMP4-HA. 200 pg 
Fam132b-MT, 200 pg Noggin-MT and 1 ng BMP4-HA mRNA were injected per 
embryo. (C) Fam132b-MT co-precipitates with BMP type I receptors Alk2-HA and Alk3-
HA. Embryos were injected with 200 pg Fam132b-MT, 500 pg Alk2-HA and 1 ng Alk3-






3.9 The conserved C1qTNF-like domain is dispensable for the BMP 
antagonizing activity of Fam132b 
 
Analysis of the predicted Xenopus tropicalis Fam132b protein sequence using 
NCBI protein BLAST revealed that it contains a conserved C-terminal C1q/TNF-
like domain (http://blast.ncbi.nlm.nih.gov/Blast.cgi). This structure that is related 
to the globular head region of the complement C1q protein is a highly 
conserved oligomerization motif and is known to bind to a variety of 
ligands(Carland and Gerwick, 2010; Kishore et al., 2004). 
 
 
Figure 23. The Fam132b C1q domain is dispensable for Fam132b-mediated BMP 
antagonism. (A) Deletion mutants of XtFam132 lacking either the C1q domain or the 
internal region between signal peptide and C1q domaine were generated. (B) Xenopus 
embryos were injected at the 4-cell stage into the marginal zone of both ventral 
blastomeres and cultivated until stage 11 for luciferase assay. VMZ – ventral marginal 
zone. (C) Reporter gene activity stimulated by endogenous levels of BMP signaling is 
efficiently inhibited by FL-Fam132b and Fam132bΔC1q, but only moderately affected 
by expression of Fam132bΔIntern. The graphs summarize the results of 5 independent 
experiments; standard errors are indicated. Three samples containing 15 embryos 
each were analysed per experiment. 100 pg of either FL-Fam132b, Fam132bΔIntern, or 
Fam132bΔC1q mRNA were injected per embryo, as indicated. Vent2b-BRE-Luc 
reporter gene activity was normalized to Renilla reporter gene activity. Vent2b-BRE-





We asked if the BMP antagonizing function of Fam132b could be mediated via 
this protein domain. For this issue we generated Fam132b deletion mutants, 
lacking either the internal region or the C1q/TNF-like domain, and analyzed 
their activity in the luciferase assay (Figure 23 A). mRNAs coding for full-length 
or mutant versions of Fam132b together with BMP-responsive Vent2b-BRE-Luc 
and BMP-independent CMV-Renilla reporter constructswere microinjected into 
both ventral blastomeres at the 4-cell-stage. Embryos were cultivated until 
gastrula stage and analyzed for luciferase activity (Figure 23B). Reporter gene 
activity, induced by endogenous BMP signaling, was efficiently blocked by 
injectionof either full-length Fam132b or Fam132bΔC1q, but only moderately 
upon injection of Fam132bΔIntern (Figure 23C). 
 
 
Figure 24. Fam132b amino-terminal domain is sufficient to block BMP signalingin 
animal cap cells. (A) Xenopus embryos were injected animally into both blastomeres 
at the 2-cell-stage, ectodermal animal cap tissue was dissected at stage 8 und 
cultivated until stage 12 for RT-PCR analysis. (B) FL-Fam132b and Fam132bΔC1q, but 
not Fam132bΔIntern inhibit BMP4 induced Xbra expression and neuralize animal cap 
tissue. 1 ng BMP4 and 100 pg of either FL-Fam132b, Fam132bΔIntern, or 
Fam132bΔC1q mRNA were injected per embryo, as indicated, and RNA extracts were 
analyzed by RT-PCR for Xbra and N-CAM expression. RT-PCR for histone H4 was 
included as loading control. CE – uninjected control embryo; CC – control animal cap 
tissue from uninjected embryos. 
 
As a second assay, we analyzed the activity of the different Fam132b versions 
in respect to BMP4-mediated induction of Xbra expressionor endogenous BMP 





the 2-cell stage with mRNAs coding for BMP4 and full-length or mutant versions 
of Fam132b. At blastula stage, animal ectodermal tissue was dissected and 
cultivated until gastrula stage for RT-PCR analysis (Figure 24A). Consistent 
with data from luciferase experiments, BMP4-mediated Xbra induction is 
repressed by expression of FL-Fam132b or Fam132bΔC1q. In addition, 
inhibition of endogenous and ectopic BMP signaling activity mediated by the 
same proteins results in activation of N-CAM expression. In contrast, 
expression of Fam132bΔIntern does neither affect Xbra induction by BMP4 nor 
activate N-CAM expression (Figure 24B).These data suggest that the internal 
region of the Fam132b protein is sufficient to mediate its BMP antagonizing 
activity. 
 
3.10 The BMP antagonizing activity of Fam132b is not highly conserved 
 
The Fam132b protein is conserved within the vertebrate kingdom, according to 
information provided by NCBI database or Ensembl genome browser 
(http://www.ncbi.nlm.nih.gov/gquery/; http://www.ensembl.org).Thus, we asked 
if Fam132b protein function is also conserved in distantly related species. First 
we cloned Xenopus laevis Fam132b using 5’RACE and 3’RACE PCR. 
Sequence comparison between X. laevis and X. tropicalis Fam132b protein 
revealed that both proteins share 86 % identity and therefore are highly 
conserved (Figure 25 C). For comparison of Xenopus Fam132b protein with 
those from other vertebrate species we used a multiple alignment, generated by 
DNASTAR Lasergene/MegAlign. General homology between these different 
vertebrate Fam132b proteins is low. However, conserved residues are 
moderately enriched in the C-terminal C1q/TNF-like domain. Seldin and 
colleagues described a motif of 6 collagenic repeats within the mouse 
myonectin/Fam132b protein (Seldin et al., 2012). This motif is highly conserved 
between human, rat, mouse, and zebrafish Fam132b proteins, but not the 
corresponding Xenopus sequence, where only two copies are present (Figure 
25 A).  
Furthermore, we generated a phylogenetic tree and determined sequence 






identities between Xenopus Fam132b proteins and those from other species did 
not exceed 30 %, while identity between mammalian proteins was higher than 
70 % (Figure 25 C). Correspondingly, a phylogenetic analysis illustrates that 
Xenopus Fam132b proteins are not closely related to Fam132b proteins derived 
from other vertebrate species (Figure 25 B). 
Figure 25. Sequence comparison of vertebrate Fam132b. (A) Sequence alignment 
of Fam132b protein sequences from Xenopus laevis, Xenopus tropicalis, zebrafish, 
human, mouse, and rat. The underlined C1q/TNF-like domain is moderately conserved 
in all species, whereas other regions of the protein are more divergent. Sequence 
alignment of putative Fam132b homologues was generated using ClustalW. Conserved 
residues are highlighted in yellow. The red box indicates the short collagen-like 
domain. (B-C) The Fam132b protein sequence is highly conserved between both 
Xenopus species, while highly divergent in comparison with other vertebrate species. 
(B) A phylogenetic tree of vertebrate Fam132b protein sequences was generated using 





different vertebrate species. Percentages were calculated using SIAS. High identity 
scores are highlighted in purple. Abbreviations and accession numbers of protein 
sequences: Xt.pro, Xenopus tropicalis (NP_001072387.1); Xl.pro, Xenopus laevis; 
Dr.pro, Danio rerio (XP_002660750); Hs.pro, Homo sapiens (Q4G0M1.2); Mm.pro, 
Mus musculus (NP_775571); Rn.pro, Rattus norvegicus (XP_002727295). 
 
 
In order to investigate if vertebrate Fam132b proteins are functionally related in 
respect to BMP antagonism, homologous Fam132b proteins were analyzed in 
the axis duplication assay. For this purpose, mRNAs coding for mouse, X. 
laevis, X. tropicalis or zebrafish Fam132b were injected marginally into 1 ventral 
blastomere at the 4-cell stage. At late tailbud stages embryos were scored for 
secondary axis formation (Figure 26 A). Expression of Xenopus Fam132b 
homologues strongly induces axis duplication, while neither zebrafish nor 
mouse Fam132b interfere with primary axis determination (Figure 26 B). 
Taken together, Fam132b protein sequence as well as protein function are only 
weakly conserved between Xenopus and other vertebrate species. 
 
 
Figure 26. Xenopus but not mouse or zebrafish Fam123 can induce secondary 
axis formation. (A) Xenopus embryos were injected into the marginal zone of one 
ventral blastomere and cultivated until early tailbud stages. (B) Xenopus homologues of 
Fam132b induce a secondary body axis in Xenopus embryos. Quantification of 
embryos showing axis duplication phenotype. Graphs show the result of at least 2 





embryos is indicated for each column. 50 pg Xenopus laevis (Xl) Fam132b, 50 pg 
Xenopus tropicalis (Xt) Fam132b, 500 pg Danio rerio (Dr) Fam132b and 500 pg Mus 
musculus (Mm) Fam132b mRNA were injected per embryo. 
 
3.11 Fam132b is expressed in ventral blood islands and circulating blood 
cells 
 
Fam132b was isolated in from Xenopus tropicalis tadpole stage embryos, but a 
detailed analysis of the spatio-temporal expression pattern during Xenopus 
development had not been performed yet (Gilchrist et al., 2004). Therefore, we 
examined Fam132b expression in Xenopus laevis embryos at various 




Figure 27. Fam132b is expressed in the VBI and in circulating blood 
cells.Transcripts of fam132bwere detected by Whole-mount in situ hybridization. 
Developmental stages of Xenopus laevis embryos are indicated at the lower right of 
each panel.Embryos are shown in a lateral view with anterior to the left. (A-B) fam132b 
transcripts are first detected at stage 34 in the ventral blood island (vbi). (D) The levels 
of fam132b in the VBI increase until stage 36. (E) By stage 38, Fam132b transcripts 
can be detected in circulating blood cells within the heart (h) and vascular structures 
such as the posterior cardinal vein (pcv) and the dorsal aorta (da). 
 
Spatial expression of Fam132b was determined by WMISH. Fam132b 





blood islands (VBI) (Fig 27 A, B). With further development this ventral 
expression domain expands towards the posterior portion of the ventral blood 
islands (Fig 27C). By stage 38 Fam132b transcripts are detected in circulating 
blood cells within the heart and the main vessels (Fig 27D).Expression of 




Figure 28. Fam132b is expressed in differentiated blood cells.(A) Fam132b is 
expressed maternally and later after the onset of αGlobin expression. RT-PCR analysis 
of the developmental stages indicated. Total RNA was harvested from staged embryos 
and subjected to RT-PCR using primer sets for Fam132b, the hematopoietic markers 





histone H4 was included as loading control. (B)Comparison of fam132b expression 
with that of hematopoietic and vascular marker genes indicates that Fam132b 
expression resembles the pattern of markers of the erythroid cell lineage, such as SCL, 
LMO2-A, and α-Globin. Fam132b expression is induced significantly later than that of 
α-Globin, indicating that fam132b is expressed in differentiated erythrocytes. 
Transcripts SCL, LMO2-A, α-Globin,mpo and ami were detected by Whole-mount in 
situ hybridization, as indicated. Embryos are shown in lateral view with anterior to the 
left Developmental stages of Xenopus laevis embryos are indicated at the top of the 
panel. 
 
RT-PCR revealed that Fam132b is expressed maternally. Zygotic transcripts 
are first detected at stage 33 and increase by stage 37. Fam132b remains 
expressed until stage 42, the last stage tested in this experiment (Figure 28 A). 
Based on the finding that Fam132b is expressed in the VBI that represents the 
origin of embryonic blood and endothelial structures, we compared temporal 
expression of Fam132b with that of hematopoietic (SCL, α-Globin) and vascular 
(msr, ami) genes. We found that Fam132b is expressed shortly after 
hematopoietic and vascular differentiation marker gene expression, as shown 
by α-Globin and ami (Figure 28 A).Comparing the Fam132b expression pattern 
to those for known myeloid (mpo), erythroid (SCL, LMO2, α-Globin) and 
vascular (ami) marker genes reveals that Fam132b expression resembles more 
the one of the erythroid rather than myeloid or vascular cell lineage (Fig 28 B). 
Taken together, these data reveal that Fam132b is expressed in differentiated, 
non-myeloid blood cells during Xenopus development. 
 
3.12 Etv2 induces Fam132b expression 
 
Etv2/er71 is a member of the ets-family of transcription factors. During Xenopus 
development it is mainly expressed in precursor cells of the hematopoietic and 
vascular lineage. Loss of function studies revealedthat Etv2/er71function is 
required for vasculogenesis, while being dispensable for 
hematopoiesis(Neuhaus et al., 2010; Salanga et al., 2010).Neuhaus and 
colleagues could show that Etv2/er71, overexpressed in Xenopus ectodermal 
explants, can induce the expression of both, hematopoietic and vascular marker 
genesfor specified and differentiated cells(Neuhaus et al., 2010). Fam132b 
expression was detected in the blood cell lineage, implicating a function for 





investigate, if Fam132b is induced by Etv2/er71, we carried out RT-PCR 
analysis for Fam132b using cDNA from Etv2/er71 expressing animal cap 
explants of stage 14 and stage 36 (Figure 29 A). Indeed, Fam132b expression 
was induced by Etv2/er71 at stage 36, as observed for several other 
hematopoietic (SCL and α-Globin) and vascular markers (msr and ami) markers 
(Figure29 B). Consistent with the data gained from the expression analysis, 
Fam132b is not expressed as early as the hematopoietic marker SCL (Fig 29 
B). These data show that, like other factors that function during blood or 
vascular development, Fam132b is induced by Etv2/er71. 
 
 
Figure 29. Overexpression of Etv2/er71 in animal caps induces expression of 
Fam132b. (A) Xenopus embryos were injected animally into both blastomeres at 2-cell-
stage, ectodermal animal cap tissue was dissected at stage 8 und cultivated until stage 
14, 27 or 36 for RT-PCR analysis. (B) Expression of both hematopoietic (SCL and α-
Globin) and vascular (msr and ami) marker genes was induced by Er71/Etv2. 
Furthermore, Er71/Etv2 activates the transcription of Fam132b. 150 pg Er71/Etv2 










3.13 Fam132b promotes vascular and suppresses hematopoietic 
development 
 
As shown above, Fam132b is expressed in the developing blood cell lineage of 
Xenopus embryos and is induced by Etv2/er71 in ectodermalXenopus explants 
(Figure 27 and Figure 29). These results seem to imply a function for Fam132b 
in the context of blood development. In order to test this further, we performed 
loss of function experiments. For this purpose, 2Fam132b antisense morpholino 
oligonucleotides were designed.These morpholinosare complementary to 
ashort sequences within the 5’ untranslated region (UTR) or the coding 
sequence (CDS)of Fam132b mRNA, where they should bind and block 
Fam132b protein synthesis.  
 
 
Figure 30. Fam132b MO1 and MO2 efficiently block reporter protein synthesis. 
(A) To test morpholino oligonucleotide (MO) activity, a reporter construct was 
generated, containing the Xenopus laevis Fam132b-5’untranslated region (UTR) anda 
part of the coding sequence (pCDS), fused to myc-epitope tag (MT) and GFP. Red 
bars indicate binding sites of the Fam132b MOs and mismatch (mm) MOs. (B) 
Xenopus embryos were injected animally into both blastomeres at the 2-cell-stage and 
cultivated until stage 11 for Western Blot analysis. (C) Both Fam132b MO1 and MO2 
block translation of the reporter construct in a dose-dependent manner, while cMO and 
mmMO1 do not affect reporter protein synthesis. 200 pg 5’UTR-XlFam132b-MT-GFP 
mRNA was coinjected with 5 ng, 10 ng, or 20 ng morpholino per embryo, as indicated. 






To ensure morpholino specificity, a contol morpholino (cMO) with irrelevant 
sequence or 5-base mismatch morpholinos (mmMO1/2) were used. These 
oligonucleotides should not bind and block translation of the corresponding 
target sequence. To test morpholino activity a reporter construct 5’UTR-
XlFam132b-MT-GFP was generated that contains morpholino binding sites, 
fused to myc-epitope tag (MT) and green fluorescent protein (GFP) (Figure 30 
A). Reporter mRNA was injected together with different doses of morpholino 
oligonucleotides animally into both blastomeres of the 2-cell stage Xenopus 
embryo (Figure 30 B). Western Blot analysis of injected gastrula stage embryos 
revealed that both Fam132b morpholino (MO) 1 and 2 efficiently block 
translation of the reporter protein in a dose-dependent manner, while cMO and 
mmMO1 do not affect protein synthesis (Figure 30 C). Although mmMO2 
contained 5 mismatches, it still blocked reporter mRNA translation albeit at 
reduced efficiency(Figure 30 C). Additionally, we found MO1to block translation 
of a reporter constructthat lacks the morpholino binding sites,indicating that this 
morpholino unspecifically interfereswith protein synthesis (data not shown). 
Thus, MO1 and mmMO2 were not used for further Fam132b loss of function 
studies. 
In order to test if Fam132b is needed for proper blood cell development, 
Fam132b MO2 and mmMO1 were injected ventrally and expression of the 
erythroid differentiation marker α-Globin was analyzed in whole embryos by 
WMISH at developmental stage 37/38. In this experiment, we did not observe 
any alteration in neither the level nor the distribution of α-Globin transcripts 
(data not shown). However, morpholinos were injected at early cleavage stages 
while the onset of zygotic Fam132b expression does not occur before stage 33 
(Figure 27). Thus, morpholino oligonucleotides might become toodiluted over 
time.  
Therefore, we used a second assay for studying Fam132b activity during 
hematopoietic development and analyzed Fam132b loss of function as well as 
Fam132b gain of function in Etv2/er71 expressing animal cap explants. 
Correspondingly, Etv2/er71 mRNA was injected along with either Fam132b 
MO2 or mmMO1, or with Fam132b mRNA animally into both blastomeres of 2-
cell-stage Xenopus embryos. Animal cap tissue was explanted at stage 8 and 





37/38. After isolation of total RNA, gene expression was determined using 
Nanostring nCounter multiplex analysis (Figure 31 A; for a complete list of 
genes analyzed see Appendix 6.1). In this process, individual mRNA transcripts 
are quantified without any amplification by hybridization with target-specific 
antisense RNA-probes, each labeled with a distinct code of fluorophores. Gene 
expression levels are determined by counting transcript-specific fluorescent 
signals (Geiss et al., 2008). 
 
 
Figure 31. Fam132b enhances expression of vascular genes at the expense of 
blood markers. (A) Xenopus embryos were injected animally into both blastomeres at 
the 2-cell-stage, ectodermal animal cap tissue was dissected at stage 8 und cultivated 
until stage 37/38 for RNA isolation. Gene expression was analyzed using Nanostring 
nCounter analysis. (B-C) Shown are graphs of selected hematopoietic (B) and vascular 
(C) marker genes; for a full list see Appendix 6.3. The graphs show the averagedfold 





errors are indicated.150 pg Er71/Etv2 and 150 pg Fam132b mRNA, and 10 ng 
Fam132b MO2 or mmMO1 were injected, as indicated. 
 
In this study, we analyzed the transcript levels of a set of genes which are 
expressed in differentiated blood or vascular cells (Figure 31 B and C). As 
described above, overexpression of Etv2/er71 inducesexpression of both 
hematopoietic and endothelial marker genes in animal cap cells (Figure 31 
Aand B). Overexpression of Fam132b caused a strong decrease in expression 
of hematopoietic genes, such as α-Globin, Gata1, EpoR, mpo, and Runx1 
(Figure 31 B). At the same time, vascular markers, such as Aplnr, Flt-1, ami, 
Etv2/er71, and VE-cadherin, were upregulated (Figure 31 C). In contrast, loss of 
Fam132b function using Fam132b MO2 caused a repression of Etv2/er71 
inducedendothelial markers, while expression of hematopoietic genes was not 
significantly altered(Figure 31 B and C). However, mmMO1 also affected 
vascular gene expression similar to MO2, at least partially.Taken together, our 
data suggest that Fam132b supports vascular development at the expense of 









4.1 Modification of canonical Wnt signaling using GR-fusion constructs 
 
Previous studies have shown that canonical Wnt signaling activity has to be 
tightly regulated over time and space to allow proper organ development. For 
instance, we have shown that early inhibition of Wnt/β-catenin signaling in the 
ventral pancreas is important to allow organ specification. In contrast, later 
during development proliferative stomach cells need high levels of canonical 
Wnt signaling (Damianitsch et al., 2009). These findings point to the importance 
of a tight temporal control of signaling modulations, if a specific developmental 
process has to be analyzed. For this reason, we generated a set of GR-fused 
putative Wnt/β-Catenin signaling modulating factors and tested these for 
Dexamethosone inducibility as well as for their ability to activate or repress 
canonical Wnt signaling activity (Figure 9, Figure 10, and Figure 11). 
Surprisingly, we found that activity of only a small subset of these fusion 
proteins could be induced by Dexamethasone (Table 7). Multiple reports are 
available that describe the analysis of novel gene functions in the context of 
specific developmental processes using GR-fused proteins(De Rienzo et al., 
2011; Domingos et al., 2001; Szeto et al., 2002; Tada et al., 1997). However, 
our data indicate that a careful functional analysis of GR-fusion protein 
inducibility in a well established and sensitive system is necessary to exclude 
unspecific protein activity. 
To date, several studies have implicated canonical Wnt signaling in pancreatic 
development. Studies in mouse revealed that specification of pancreatic 
precursor cells needs low levels of nuclear β-catenin (Damianitsch et al., 2009; 
Heiser et al., 2006). Correspondingly, we found that early activation of canonical 
Wnt signaling causes a reduction of the dorsal pancreas, pointing to this 
inhibitory role of canonical Wnt signaling during pancreatic specification 
(Figure12), (Melchert, 2007). However, also late stimulation of Wnt signaling, 





compartment in the mouse, caused a loss of dorsal pancreas (Figure 12), 
(Heiser et al., 2006; Melchert, 2007; Murtaugh et al., 2005).  
Additionally, McLin and colleagues postulated a model, in which Wnt/β-Catenin 
signaling activity has to be low in the anterior and high in the posterior gut tube 
to allow specification of foregut and hindgut tissue, respectively (McLin et al., 
2007). Correspondingly they could show that early ectopic activation of 
canonical Wnt signaling in the Xenopus anterior endoderm causes a repression 
of pancreatic marker gene expression in both dorsal and ventral pancreas. In 
contrast, repression of Wnt/β-Catenin signaling in the posterior endoderm 
before neurulation induces ectopic expression of pancreatic genes in the 
hindgut (McLin et al., 2007). Contradictory to these data, we observed that early 
pan-endodermal repression of the Wnt signaling resulted in a reduction of the 
exocrine pancreatic compartment (Figure 12), (Forchmann, 2009). However, it 
is important to mention that we repressed Wnt signaling in the whole endoderm, 
resulting in the same level of signaling activity both anteriorly and posteriorly. In 
contrast, McLin and colleagues targeted Wnt repressors specifically to those 
blastomeres contributing to the posterior gut tissue only (McLin et al., 2007).  
Interestingly, Lyons and colleagues observed that both repression and 
hyperactivation of canonical Wnt signaling in the developing pronephros result 
in impaired pronephric tubulogenesis in Xenopus(Lyons et al., 2009).  
Nevertheless, the observed phenotypes caused by overexpression of Wnt 
signaling modulating GR-fusion constructs were difficult to interpret, making it 
complicated to further analyze the role of canonical Wnt signaling in Xenopus 
endodermal development using these given tools. 
 
4.2 Fam132b, a novel BMP antagonist 
 
In this study, we have identified Fam132b as a novel antagonist of the BMP 
signaling pathway. To date, Fam132b has not been implicated in cell signaling 
and no function for Fam132b during development has been reported. Therefore, 
we are interested in investigating the mechanism by which Fam132b 
antagonizes BMP signaling activity. Multiple proteins are known to regulate 





activity of either intracellular or extracellular mediators of the pathway (Ramel 
and Hill, 2012; Walsh et al., 2010).We could show that Fam132b is a secreted 
protein and that BMP signaling activity mediated by a constitutively active BMP 
type I receptor is not inhibited by Fam132b (Figure 20, Figure 21). Therefore, 
Fam132b most likely represents a novel extracellular BMP antagonist, rather 
than a pseudoreceptor or a cytoplasmic inhibitor of BMP signal transduction. 
BMP signaling is initiated via formation of a heterohexameric complex between 
a BMP ligand dimer and BMP type I and type II receptors (Figure 32 A). To 
date, the most common extracellular mechanism of BMP inhibition is mediated 
by proteins such as Noggin, Chordin or members of the DAN family that directly 
bind to BMP ligands and thereby block BMP/receptor interaction (Gazzerro and 
Canalis, 2006; Piccolo et al., 1996; Smith and Harland, 1992). In this study, Co-
Immunoprecipitation experiments using epitope-tagged versions of Fam132b 
and BMP4 revealed that there is only weak interaction between these proteins, 
compared to the formation of the Noggin/BMP4 complex (Figure 22). Therefore, 




Figure 32. Model for Fam132b mediated BMP antagonism via receptor 
interaction. (A) Activation of the BMP signaling pathway. A BMP ligand dimer (purple) 
forms a heterohexameric complex with BMP type I (yellow) and type II receptors 
(orange) and autophosphorylation of the type I receptor is initiated. Activated type I 
receptors transduce the signal into the cell and trigger target gene regulation.(B-C) 
Fam132b (red) can bind to BMP type I receptors, suggesting different modes of action 
for Fam132b mediated BMP antagonism: (B) Fam132b binds the complex of BMP 
proteins and BMP receptors and inhibits signal transduction into the intracellular space. 






In contrast to those BMP binding proteins described above, Follistatin interacts 
directly with BMP but does not prevent BMP/receptor complex formation 
(Iemura et al., 1998). Additionally, it was shown that Follistatin can interact with 
both type I and type II TGF-β receptors (Thompson et al., 2005). We could show 
that Fam132b interacts with the BMP type I receptors Alk2 and Alk3, implying 
that Fam132b might inhibit the BMP pathway in a similar way as reported for 
Follistatin (Figure 22, Figure 32 B). 
However, CoIP experiments revealed only weak interaction between BMP4 and 
Fam132b (Figure 22). Hence, we propose a mechanism for Fam132b 
antagonism in which Fam132b directly binds to the BMP receptor complex, 
blocking it from binding to the BMP ligand (Figure 32 C). A similar mode of 
action has already been described for other BMP antagonists, such as BMP-3 
and inhibin. However, so far these proteins have been reported to interact with 
TGF-β type II receptors (Gamer et al., 2005; Wiater and Vale, 2003). The 
question, if Fam132b interacts with BMP type II receptors as well, remains to be 
answered. 
While Chordin and Noggin were shown to specifically antagonize BMP signaling 
activity, the majority of extracellular BMP antagonists, including BMP and 
receptorinteracting proteins, were shown to interfere with other pathways as 
well (Gamer et al., 2005; Gazzerro and Canalis, 2006; Harrison et al., 2006). 
Interestingly, we found that Fam132b neither inhibits activin nor FGF mediated 
signal transduction, indicating that this protein is a selective BMP antagonist 
(Figure 19).  
 
4.3 Fam132b, a member of the secreted C1q domain containing protein 
family 
 
Analysis of the Fam132b protein sequence revealed that Fam132b contains a 
C-terminal C1q/TNF-like domain (Figure 23). This structure is related to the C-
terminal globular ligand binding domain of the complement factor C1q. The C1q 
protein is a key player in innate immunity and induces the classical pathway of 
the complement system by antigen binding via the globular C1q domain. 





inflammatory response, phagocytosis or lysis of pathogenic cells (Janeway et 
al., 2001). 
The globular C1q/TNF-like domain is not only found in the C1q protein itself, but 
also in C1q and TNF type protein families (Figure 33). This protein domain is 
characterized by the ability to fold into 5 pairs of anti-parallel β-strands forming a 
jelly roll beta barrel structure (Kishore et al., 2004). C1q- and TNF-like factors 
can be expressed as soluble plasma or membrane bound proteins and were 
shown to form oligomeric complexes with other members of the C1q/TNF-like 
superfamily (Schaffler and Buechler, 2012; Shapiro and Scherer, 1998). 
Members of this protein family exhibt a broad range of biological functions, 




Figure 33. Cartoon depicting the structural motifs of the C1q family members. 
Proteins of the C1q family have a C-terminal globular C1q (gC1q) domain and form 
homotrimeric (Adiponectin, Saccular collagen, Type VIII and X collagen, EMELIN-1 and 
multimerin) or heterotrimeric (Hibernation protein, Precerebellin and C1q) complexes. 
The majority of C1q-like proteins contain a collagen-like region, with the exception of  
precerebellin and multimerin. Elastin microfibril interface-located protein (EMELIN) 
contains two leucine zippers, while Multimerin has an RGDS motif. Both EMELIN-1 and 





forming coiled-coil structures.  Many C1q-like proteins exhibit cysteine residues as well 
as possible glycosylation sites (from Kishore et al., 2004). 
 
Furthermore, several members of these protein families have been implicated in 
cell signaling pathways, such as the MAPK pathway or NF-κB signaling(Kishore 
et al., 2004).However, a role for any of these factors in BMP antagonism, as 
observed for Xenopus Fam132b in the context of this study, has not been 
reportedso far. Interestingly, we found that the Fam132b C1q domain is 
dispensable for its BMP antagonizing function, suggesting that this structure 
might exhibit functions different from BMP inhibition (Figure 23, Figure 24). 
Xenopus tropicalis Fam132b protein is predicted to share structural similarities 
with the secreted subfamily of C1q domain containing proteins (sghC1q), such 
as Precerebellin (Figure 33). These are the N-terminal signal peptide, the C-
terminal gC1q domain and the lack of an N-terminal collagen-like region (Figure 
33), (Carland and Gerwick, 2010).Several studies in different fish species have 
described an increase in transcription of multiple sghC1q factors following an 
inflammatory stimulus (Carland and Gerwick, 2010; Gerwick et al., 2007; 
Gerwick et al., 2000; Nakamura et al., 2009).If Fam132b has a function during 
innate immune response was not analyzed. 
Regarding database information, Fam132b homologues exist in different 
vertebrate species. But expression and function of this protein during 
development have not been described so far. However, a recent study delivered 
insight into the function of mouse Fam132b, termed myonectin/CTRP15, in 
tissue homeostasis. Seldin and colleagues found that the myokine myonectin is 
expressed and secreted predominantly by skeletal muscle of adult mice. The 
glycosylated protein can complex with other C1q domain containing proteins 
and was shown to regulate fatty acid metabolism (Seldin et al., 2012). In 
Xenopus early embryonic development, Fam132b transcripts are not detected 
in myogenesis, and expression or function of Fam132b in the adult frog was not 
analyzed within this study.  
Sequence comparison of Xenopus Fam132b with related proteins revealed that 
they share only moderate sequence identity, and the most considerable 
difference between these proteins was the presence of an amino-terminal 
collagen-like structure. Different from Xenopus Fam132b proteins, homologues 





collagen helix (Figure 25). Furthermore, both Xenopus laevis and Xenopus 
tropicalis Fam132b, but not homologues from mouse or zebrafish could induce 
secondary axis formation in Xenopus embryos (Figure 26). In conclusion, we do 
not expect the Xenopus Fam132b protein, analyzed in this study, to be the true 
functional homologue of mouse myonectin/Fam132b or the protein referred to 
as zebrafish Fam132b. 
 
4.4 The role of Fam132b during development of blood and vasculature 
 
BMP signaling has been shown to regulate hematopoiesis and development of 
the vascular system (Hartenstein, 2006; Lugus et al., 2005). In this study we 
identified Fam132b as a novel BMP antagonist which is expressed in the ventral 
blood islands and is induced by Etv2/er71, together with other markers of 
hematopoiesis and vasculogenesis (Figure 27, Figure 29). We found that 
coexpression of Fam132b with Etv2/er71 in animal cap explants caused a 
severe downregulation of Etv2/er71 induced hematopoietic genes (Figure 31 B).  
Interestingly, correlating observations have been made upon repression of 
endogenous or ectopic stimulation of BMP signaling activity in Xenopus 
embryos. While ectopic expression of BMP4 in animal cap explants induces 
stable expression of terminal erythroid differentiation markers, ventral 
mesodermal explants as a well as whole Xenopusembryos expressing a 
dominant negative BMP receptor loose the potential to activate the 
hematopoietic program (Maeno et al., 1994; Zhang and Evans, 1996). Initially, 
this loss of hematopoietic lineage was thought to be a result of impaired 
specification of ventral mesoderm, which is induced by high levels of BMP 
signaling and mainly contributes to the primitive erythroid compartment (Dale 
and Wardle, 1999; Dosch et al., 1997). However, using conditional inhibition of 
BMP signaling in Xenopus embryos Schmerer and Evans could show that BMP 
signaling is required for primitive erythroid cell differentiation, independent of 
any early requirement for cell specification (Schmerer and Evans, 2003). 
In this study, we generated hemangioblast like cells by overexpression of 
Etv2/er71 in pluripotent Xenopus animal cap tissue. Given that Fam132b 





ectopically expressed Fam132b interferes with the pro-hematopoietic activity of 
BMP signaling in the context of hemangioblast development into either 
endothelial or blood cells (Figure 34). 
However, knockdown of Fam132b in Etv2/er71 expressing animal cap explants 
did not cause a significant upregulation of hematopoietic gene expression 
(Figure 31 B). This result correlates with the finding that endogenous Fam132b 
is induced relatively late in Etv2/er71 expressing animal cap explants (Figure 
29).  In addition, Fam132b expression in the whole embryo was first detected 
after blood cell differentiation (Figure28), making it unlikely that regulation of 
hematopoietic or endothelial cell fate decision is indeed the endogenous 
function of Fam132b. Therefore, it would be interesting to analyze 
hematopoietic gene expression in Etv2/er71 expressing animal cap 
tissuetreated with recombinant Fam132b protein at later developmental stages. 
 
 
Figure 34. Model for Fam132b activity in the context of cell fate determination in 
Etv2/er71 expressing animal cap cells. Etv2/er71 induces either hematopoietic or 
vascular cell fate. Fam132b represses blood cell development while promoting 
vascular fate, possibly by inhibition of BMP signaling activity or by using an alternative 
mechanism. 
 
BMP signaling activity does not only regulate the development of the 
hematopoietic cell lineage but is also relevant in the formation of endothelial 
structures. For instance, Walmsley and colleagues could show, that Xfli-1 





absence of BMP signaling activity (Walmsley et al., 2002). Consistant with 
these data,studies in mouse revealed that a loss ofthe BMP signal transducer 
Smad5 allows the formation of a primitive vascular plexus but a mature vascular 
network is not established(Chang et al., 1999; Yang et al., 1999). Furthermore, 
recent studies demonstrated that ectopic BMP signaling in endothelial cells 
inhibits the expression of apelin, a secreted factor that signals via its receptor 
APJ/Xmsr and stimulates proliferation and migration of endothelial cells during 
angiogenesis (Ciais and Bailly, 2012; Larrivee et al., 2012; Poirier et al., 2012; 
Ricard et al., 2012). Taken together, these data suggest a biphasic role for BMP 
signaling during vascular development. While the pathway has to be 
downregulated within the early phase of vasculogenesis, BMP signaling activity 
is necessary for proper maturation of the vascular system.  
We could show that Fam132b gain of function in Etv2/er71 expressing animal 
cap cells severely enhanced the expression of endothelial genes (Figure 31 C). 
We conclude that, in this experimental system,  Fam132b promotes the 
development of the vascular compartment at the expense of the hematopoietic 
cell lineage and that this regulatory function could be mediated by its BMP 
antagonizing activity (Figure 34). 
However, although Fam132b loss of function did not significantly alter 
hematopoietic gene expression, transcript levels of vascular markers were at 
least 2 fold decreased upon Fam132b morpholino injection (Figure 31). Given 
thatFam132b induction by Etv2/er71 in animal cap explantsoccurs long after 
endothelial cell specification (Figure 29), we suggest that Fam132b promotes 
endothelial development by a mechanism other than regulation of cell fate 
decision. For instance, Fam132b might be involved in regulation of endothelial 
cell fate maintenance. 
Functional analysis of Fam132b in the context of blood and endothelial 
development was carried out in Etv2/er71 overexpressing animal cap explants 
which reflect an artificial system. However, it is reasonable to study protein 
activity in the whole embryo. But so far, loss of Fam132b function using 
microinjection of morpholino oligotides did not affect hematopoietic or vascular 
development in Xenopus embryos. The absence of a knockdown phenotype 
might be due to the late expression of Fam132b (Figure 27, Figure 28). 





tool for investigation of gene activity during early developmental processes. 
However, this system is limited, if late developmental processes are analyzed, 
since morpholinos are diluted with every cell cleavage. Alternatively, targeted 
gene disruption using engineered transcription activator-like effector nucleases 
(TALENs) was shown to be a very efficient tool for loss of function studies in rat 
and zebrafish, but also in Xenopus(Huang et al., 2011; Lei et al., 2012; Tesson 
et al., 2011). Therefore, TALENs approach will be used in future experiments to 







In this study, 13 GR-fusion constructs were tested for their potential to modulate 
canonical Wnt signaling and for hormone-inducibility. However, only 4 of them 
showed the expected phenotype and were used for endodermal 
overexpression. Since both activation and repression of Wnt signaling caused 
the same reduction of exocrine pancreas we proceeded with expression cloning 
to investigate novel regulators of canonical Wnt signaling. Interestingly, in this 
screen we identified Fam132b as a novel extracellular BMP antagonist that 
selectively inhibits BMP signaling probably by binding to the BMP receptor. 
Previous studies have reported that regulation of BMP signaling activity is very 
important for development of the blood circulatory system. We found that 
Fam132b is expressed in the blood and vessel forming compartment during 
Xenopus development and that Fam132b regulates development of 
hematopoietic and endothelial cells in Xenopus tissue culture. Many studies 
have focused on early processes in the context of hematopoiesis and 
vasculogenesis, while later developmental events are only poorly characterized 
in Xenopus. We observed that Fam132b is expressed during this late 
developmental phase and it will be interesting to further investigate the function 
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6.1 Genes analyzed by Nanostring nCounter 
 
The nCounter gene expression Code set was purchased from nanoString® 
TECHNOLOGIES (Seattle, USA). Genes analyzed by Nanostring nCounter are 
shown in Table 8. 
 
Table 8. Summary of Gene symbols, Accession numbers, Target regions and 
Target sequences for all genes analyzed by Nanostring nCounter. 
Gene Accession number 
Target 
Region Target Sequence 
ami NM_001094624.1 716-816 
GCCTATCGAAGAAGCCAGGCATCTACACACTCATTGCACCTTACAAATCCTGGATAATGGAAACC
ATGTATAATGCTACTCTACTCCCATCCCCTTTGTG 
apelin-a/b NM_001097784.1 161-261 
TGAACCCAAAAATGGTCCGTAACTCTGCACCTCAACGGCAAGCCAACCGGAGAAAACTCATACG
TCAAAGACCCCGTCTTTCACACAAGGGCCCAATGCC 
Aplnr-a/b NM_001090637.1 155-255 
CATGCGATGAAACAGACTGGGATTTCTCCTATTCTCTGCTACCTGTCTTTTACATGATCGTGTTTG
TCCTTGGACTCTCAGGGAATGGAGTGGTCATCTT 
epo NM_001197281.1 798-898 
TTTTTTACGAGGTAAATTGAGACTACTAGTGATGGCAGTGTGCCGGGAGGCTAGTCTACCAACGT
GAGGTCTCCTCGCTTACCCAATCATCCCTACTGAA 
epor NM_001095704.1 688-788 
CATTGTCCCAGCTGCATACACTGTCACAGTAAGATGCAAAGCAGATGGTGTTTCATATAACGGCT
ACTGGAGTGATTGGACGGCACCTATTACCATAGCG 






GATA-1-b NM_001085775.1 389-489 
GTACCCCTCAGCTGCATCAGCCTTAGGCTCTATAACTTCTCCTCCTTTGTATAGTGCTACCCCTTT
CTTATTGGGTTCAGCACCTCTAGCAGAACGTGAC 

































VEGF C NM_001095814.1 658-758 
CTCTACCCCGAATCCTGGAAAATGTTTAAGTGCCAACTACGACAAGGAGGCACCACCGGATTTG
ACACCAGGAGGGATGACAGTTTTAAATTTGCAGCTG 
Vegfa-a/b NM_001085589.1 441-541 
GTTACAACATCACCATGCAGATAATGAAAATAAAGCCTCATATAAGCCAACATATAATGGATATGA
GCTTTCAGCAGCACAGTCAGTGTGAATGCAGACC 










αT3-Globin NM_001086328.1 40-140 
CAACTAGCTCCCTCTTGTCAAGATGACTCTGACCGACAGTGATAAGGCTGCAGTTGTTGCTCTGT
GGGGCAAAATCGCACCCCAAGCTAATGCCATTGGA 








Follistatin NM_001090590.1 355-455 
ATGTAAAATGAACAAGAAGAACAAGCCGAGGTGTGTCTGCGCTCCGGATTGTTCCAACATTACTT
GGAAAGGTTCAGTGTGCGGAATTGATGGCAAAACC 





















Siamois NM_001085836.1 40-140 
ATTGTCTCTACCGCACTGACTCTGCAAGATGACTACATCAAATTCACTCCAAGGAACCAAAACAT
GGCCTGCCACGCTGAAATTATTGGGATATTCCATG 
Xnr3 NM_001085790.1 138-238 
AGAAAGTCCATCAGTCCAGATTCTATCCTAAAGGACACATCCACAGATATTGGAGCCAGAGAATT
TCAAGGAAGGAAGTTCCCCAATTTTATGATGCAGC 
















Gene Accession number 
Target 
Region Target Sequence 
NCAMa/b NM_001087827.1 44-144 
CATCTGGACTTTATATTTCATAGGAACTGCAGTGGCGTTGGAAGTGAACATTGTTCCAGATCAAG
GAGAAATAAGCCTTGGGGAGTCCAAATTCTTCCTG 
Sox2 NM_001088222.1 901-1001 
CCGGGCATGTCTCTGGGATCCATGGGCTCGGTAGTCAAGTCGGAATCCAGCTCCAGTCCACCTG
TAGTCACCTCTTCTTCCCATTCGCGGGCTCCGTGCC 
Sox3 NM_001090679.1 998-1098 
GCTCACTCACATATAACACTTTGTGCCCTTTGCTAAAGACGCTTTACTTGCCTGCTGGCAACTATC
AGACTGCCGCATAAAACATTTAAAAAAAAAAATC 
MyT1 NM_001088192.1 684-784 
GAGCTAAACAATGAAAAGCCAACTTCAGTAAAGTCGGGTCAAGCGGAAATAGAACAACTTATGGT
AGAAGAGGCGTGTGAGAAAGAAATCATCATCCAGA 





BMP7.1 NM_001087397.1 289-389 
CAGGTTCTGTTCTCCTTTGGACATACTTCTTGTGGAGGATCATCCTGGCTGACTTCACCTTGGAC
AATGAGGTGCACTCTAGCTTTATCCAGAGGAGGTT 
FGF4a NM_001085823.1 89-189 
TCCAGAGAAACGACACCGTGGAACGGCGATGGGAGACCCTCTTTTCCAGGTCCATGGGGGAAA
AAAAGGATACGAGTCGGGACAGTGACTATTTGCTGGG 













Mix2 X58772.1 62-162 CTGCGCCCCTTTACTCACCGCAATGTCTTCTCCCAGGAGGATCAAAGAGGATTTAAGCTCGGATGAAGAGGGCCAAGTGCACCCTACGCTCTCCCCATCT 





er71/etv2 NM_001096131.1 182-282 
CAAGTCGCGAAATTCAGCTGTCCAGGGATTCAAAAACTCCTTGAGAGAAGAGATCAGAGATTTGG
TGCAAGCAGAGCCTGTCGCGAAATTCAGCAAGATG 
erg-a (v-ets) NM_001085840.1 96-196 
TAAAATCAGCTAACTGGACCACATCATTTGATTTATCTTCTGACCCGGAGTAGCCAGAAAAACAA
GAGATTTGCTACTAAGGAAGCTGATTGTTTTCTCG 
erg-b NM_001085841.1 5-105 
TAGCCACTCACTCACACGAAGAGATTACACATTCAGACTGGCTGCTGCTCCTGCTGGAGTCACC
ACAACATTCAGTCCAGCCTCCTTCTATCCACCCTCC 





vegf D (figf) NM_001127797.1 293-393 
TTCTCTTACTCACCATGTCCATTAAAATGGGCATTGGCAGCTGTATCCTCTCTAGTGTTTAACGGC
TGGCAACGCGCTCTACCAATATGATTAGACCGTG 
SPIB-a FJ644945.1 1074-1174 
TGTGAGCTCCTCAGAAAGAGGAAAGTGACGGAACTTAAATGATGTGGTAGTGATGTTGGTAGAAA
ACCGTAGATTAGGAGTTTAGAGAATGAAGAGGAGA 
SPIB-b FJ644946.1 985-1085 AATCTTGGCCTAAATTTGCACTGAAGACCTTGGAAAGGAGCTTGCACAAAGGACAAGAGTCAAGAAGGCATCAAATCATTCATCATCAATGGACCCGTGT 
numb GQ214766.1 625-725 
AGGCGATGGATCTGTCACTGCTTCATGACTGTTAAAGATACGGGAGAGAGGCTCAGCCATGCTG
TTGGATGTGCATTTGCCGCTTGTCTGGAGAGGAAGC 
lipase endothelial NM_001090061.1 298-398 
GCTTTCGGACGAAAACGATGTTGTGCCAGAAACGCATCCCCATGTCAAGTTTAACGCCCACTTCT
CCAAACATGACCGTGGGTGCTTTCTATTTCCTGGC 
bmper NM_001095672.1 208-308 
TCCTTGTACCTCTTGTGTGTGCCTGAACAAAGAAGTTACCTGCAAACGAGAGAAGTGCCCAATAC
TGTCCAAGGATTGCGCTTTGGTTATAAAGCAGAGA 
pdgf-a NM_001087835.1 725-825 
GAACTGTTATATACGAGATACCTCGTAGCCAAATTGATCCAACATCTGCCAATTTTCTGATCTGGC
CTCCATGCGTGGAGGTGAAACGATGCACGGGATG 
STAT-5 NM_001090421.1 844-944 
GACTTGTTGCAGACATGGTGTGAAAAGCTTGCGGACATCATCTGGCAGAATCGGCAGCAAATCA
GACGAGCTGAGCACCTTTGTCAGCAGTTCCGCATCC 
Castor EF666978.1 3-103 AAACACACATTTTCCTTTACTTGGAAAGTCACCCAAAGCAGTCCAAGTGCAGAGATTCCAAAAATCAATCCAATAAAACAAAGATAAGAAGAAAGAACAT 
hand1 NM_001085659.1 107-207 
TGATTGTGGTGCTTCCCTGAGGAGTGATTGCAGAGTAGCTGAGGATGTTCTGATGCCATATCTAA
TGGCTTCCCACTGAGGAGGTGCCAGAAGTTGTTTT 








wnt11 NM_001093610.1 229-329 
AAAGGACTTATCAGGATATTTACTGGAAAAGTTACCGGGGGATTCACGCAGCATAATGGCACGTT
GCTTACGGCCATAACCCTAAAGGATTAATTTCAAC 
















patched2 AB037688.1 1469-1569 
CAAAGAAAGTTTGTAGAGCAAGCACAACAGTCCGTCCCACAGAACTCATCCCAGGACATCCATG
CTTTTTCTACCACCACACTTAATGACATCATGAAGT 
smoothend AF302766.1 1824-1924 
GATGTCTCGGTAACACCTGTAGCAACTCCAGTTCCACCAGAAGAAAGGGACCAGTGGTTTATTGA
AGGAGATATACCTCAGGGGATGGTTAAGAAAATGT 
























HIF-1a NM_001086980.1 86-186 
TCGTACGGTCGGATTAAACCGGAGGGATTGCGTCGTAAAATATTCCCTGCCGGGGTTGCCGGAG
AGATCTGACCTTGCCAACGAATCGTCTTTCGCGTGT 















myosin light chain 1 NM_001086783.1 920-1020 
GGAGCACTGTAAAAAATAAAAAAAAGACATGTCAATAAACACCTTTGCTAATTTGGTGGCTACCAA
GTCTATTTATTTCATCTGCCAAAGGCTTTGGGCC 






Gene Accession number 
Target 
Region Target Sequence 













BMP4-b NM_001101793.1 200-300 
AAGAAAGTCGCGGCCGACATTCAGGGAGGAGGTCGCAGGTCGCCTCAGAGCAATGAGCTCTTG
CGGGATTTCGAGGTGACGCTGCTGCAGATGTTCGGAC 








smad5 (smad4.2-b) NM_001090989.1 187-287 
TCTGGCTTTTTGTACCACTAATTGGTTCAGTCCAATAAACCCCATGGAGGTGTAACAACAAGGGC
AAAAGATGGCGTTTGCCAGCCTAGAGCTCGCCCTG 


















fgfr-4 NM_001087718.1 230-330 
TTGCTTTCGGTTCGGGGATTTATTTTGTGCCGCTGAGGAACGGAGACTAGTTCTTATGAATGGGA
TCACGAGTAACCTTCTAACGGCACCCGGAGATCCG 
mix1-a NM_001087825.1 974-1074 
AAGAACATCAAACCAGAGGTGTATACTACCAGCCCTCAGATACCTGTATCTACCACTTCAAGCCA
GGTGAGCTTGTTTGCCAACCAAGAGCCGTGTCACA 








Lmo4 AJ511277.1 75-175 AGTCTACCACCACGGCGGTGAGCAGTAATGGCAGCCCACCCAAAGCTTGTGCCGGGTGCGGAGGGAAGATTGGCGACCGCTTCTTGCTCTATTCTATGGA 



















Sizzled NM_001088279.1 406-506 
CCAGCTGGGGAAGACATGTGCTTGGACACTCTCAGCAAAGAGTATCAGTACTCCTATAAAGAATT
GCCTAAGCCAAGTTGCCAGGGCTGCCCGCTGATTG 
dkk-1 NM_001085592.1 770-870 
GAGATTTTCCAGCGTTGTCACTGCGGTGCCGGACTCTCGTGCCGGTTACAGAAAGGAGAATTTA
CAACTGTCCCTAAAACATCGAGACTTCACACTTGCC 
dkk-2 BC169368.1 1059-1159 
GAGAAAGAAAGGATCTCACGGCCTGGAGATTTTTCAAAGATGTGACTGTGCAAAAGGGCTATCTT
GCAAAGTATGGAAAGATGCCACCTACTCTTCAAAG 
dkk-3 NM_001127818.1 774-874 
GTTCACTCAAATCTCCTGTTCCCTGTTTGCACCCCTCTGCCAGTTAAAGGGGAACCTTGCTTCGA
CCCATCCAATAAATTCGTAGACATACTGAACTGGG 
chibby NM_001088793.1 44-144 
AGAGTTTGTGCGGGAAAGGCAGTAAGTTTGGTTGAGACAAAGCGCATAGTGAACTAATCTTCAG
GGAAGATGCCCTTATTCGGGAACACGTTCAGCCCAA 















klf2 NM_001086961.1 283-383 
GACAATCTGATTCGGATTTGGGATGGCTCTGAGCGAGACCATTCTCCCTTCTTTCGCTACGTTTG
CAAGCCAAGATAGGTGGAAGTGTGAGTATGAGTCC 
Ferritin (fth1-a)) NM_001090588.1 453-553 
TCTTCTTTCTTTTCAGTTTCATCCACCTCCTCTCTGGCTCTGAGTAGAGTTCTTGCTTCAACAGTG
TTTGAACGGAACCCTCTCTGAGTCTTTTTTAGAC 
Ferroportin (slc40a1) NM_001093357.1 785-885 
GCTACGATAAGAAGAATCGATCAACTGACAAACATTTTAGCTCCACTGGCTGTAGGACAAATAAT
GACCTTTGGTTCCCCAGTCATAGGCTGTGGATTTA 
ODC NM_001086698.1 855-955 
GGATATAATTGGTGTGAGTTTCCATGTTGGCAGTGGCTGCACTGATCCACAGACTTATGTACAAG
CTGTCTCAGATGCACGATGTGTCTTTGACATGGGG 
H4 NM_001094457.1 655-755 
CCACGCCCCTTCTCCCCATAAAATCAGTTACAGGCTCTCGGGCTCTTTTGCTCTTGCCGGATGGA
AATTACTGTTGCTGCTCAGCGTCTCACAGAACTCC 













6.2 Primary gene expression data 
 
Primary gene expression data from Nanostring nCounter analysis are shown for 




Table 9.Primary gene expression data from Nanostring nCounter analysis for 
experiment 1. 
Gene experiment 1 
CE CC Etv2 Etv2/ MO2 Etv2 /mmMO1 Etv2 /Fam132b 
AT3-Globin 29920 16 2326 5449 1568 3 
Aplnr-a/b 1161 38 1266 282 269 2309 
BMP2-a/b 553 203 261 302 245 64 
BMP4-b 115 244 170 70 104 59 
BMP7.1 1051 448 349 286 244 190 
BMP7.2 11 2 5 6 1 1 
Castor 275 43 54 40 23 69 
Cerberus 20 16 15 6 2 4 
FGF4b 18 4 8 9 6 1 
Fam32B 59 4 7 13 5 2532 
Ferritin (fth1-a)) 21740 25564 17750 19039 29781 12265 
Ferroportin (slc40a1) 2642 3226 1887 1761 1810 528 
Follistatin 842 18 82 9 4 191 
Foxc1a 639 52 40 22 26 36 
GATA-1-a 127 11 36 58 22 2 
GATA-2 284 147 142 208 167 147 
GATA-3 647 686 371 347 362 196 
Gli2 509 144 82 76 60 144 
Gli3 321 81 50 48 50 74 
Gli4 348 34 27 19 26 85 
H4 18 26 33 21 14 5 
HIF-1a 1151 742 703 702 603 437 
HIF-2a (epas1) 499 1314 549 574 533 217 
LMO-2 413 1 235 242 134 103 
Lmo4 441 77 132 112 56 109 
Mix2 446 1689 854 848 796 176 
Msx2 1544 2893 1610 1216 1308 682 
MyT1 1448 79 54 60 43 307 
NCAMa/b 1891 3 72 3 1 364 
Noggin 267 22 41 14 15 58 
ODC 28270 8876 6882 8066 5611 6591 
PECAM1 26 1 13 8 2 17 
Prox-1 664 14 50 42 34 30 
SCL 387 4 106 147 64 97 
SPIB-a 150 34 696 1836 1599 42 
STAT-5 758 1661 572 648 660 113 
Siamois 8 7 4 1 4 2 
Sizzled 91 75 84 130 102 33 
Sox2 2630 48 141 62 66 713 
Sox3 852 45 48 22 26 246 
TGFB-1 702 54 139 157 100 139 
VEGF C 254 18 35 42 33 24 




Gene experiment 1 
CE CC Etv2 Etv2/ MO2 Etv2 /mmMO1 Etv2 /Fam132b 
Vegfa-a/b 527 69 60 65 54 40 
Vent1 28 14 21 30 15 4 
Vent2 17 13 16 14 8 4 
Xbra-a 41 5 5 6 5 7 
Xbra-b 128 5 5 1 1 1 
Xhex 160 8 327 299 228 216 
Xnr3 9 8 8 8 6 3 
Xpo 985 1104 613 671 544 217 
actb 164684 137150 102995 127872 121969 51702 
activin B 205 32 18 14 18 46 
admp2 9 8 9 7 4 4 
ami 2896 8 5234 2924 1640 10477 
angiopoitin (angpt1) 190 5 7 2 1 15 
apelin-a/b 306 19 29 19 11 24 
bFGF (fgf2) 172 20 20 19 16 20 
bmper 431 53 92 72 47 91 
chibby 8 8 9 8 10 2 
chordin 59 1 9 3 5 7 
ctroponin 144 2 1 4 2 6 
dkk-1 131 84 93 60 68 8 
dkk-2 38 8 12 4 7 1 
dkk-3 297 59 47 31 26 183 
egln1 (PHD2) 719 581 355 196 218 131 
egln2 (PHD1) 29698 40733 23368 23224 22558 6741 
egln3 (PHD3) 88 45 40 51 49 48 
egr1-a/b 168 827 477 508 674 349 
endoglin 87 1 72 42 42 94 
epidermal Keratin 30825 74729 42790 59999 40719 16295 
epo 21 5 18 11 4 5 
epor 114 15 18 28 22 1 
er71/etv2 87 25 310 102 99 612 
erg-a (v-ets) 263 2 97 89 56 68 
fgfr-1 245 52 51 22 24 48 
fgfr-2 909 398 258 279 218 154 
fgfr-3 358 38 41 18 14 62 
fgfr-4 876 54 135 109 70 161 
flk-1 85 8 125 51 30 145 
g6pd 904 417 452 1104 1385 208 
gapdh 8710 16699 8935 4007 5957 463 
hand1 398 3 12 10 5 2 
hand2-a 995 119 72 97 64 52 
indian hedgehog (bhh) 46 3 9 6 3 2 
jagged-1 1068 154 166 99 90 209 




Gene experiment 1 
CE CC Etv2 Etv2/ MO2 Etv2 /mmMO1 Etv2 /Fam132b 
lipase endothelial 66 30 47 37 30 9 
lysocardiolipin acyltransferase 1015 964 552 596 521 233 
mespa-a/b 4 2 1 2 1 1 
mix1-b 6 7 1 9 2 2 
mpo 3911 20 9012 18394 12802 22 
myosin light chain 1 20118 9 255 7 1 10 
nkx2.5 171 13 10 21 13 39 
notch-1 1396 140 235 169 147 459 
nr2f2 (COUP.TFII) 514 22 35 11 11 119 
numb 397 605 363 360 298 124 
patched1 572 46 53 17 20 66 
patched2 2314 7 141 24 24 169 
pdgf-a 185 19 22 11 15 30 
phospholipase C gamma 1 (plcg1) 246 60 85 28 35 87 
runx1 127 128 390 503 292 105 
smad1-a 1176 575 429 401 355 263 
smad5 (smad4.2-b) 57 59 37 21 24 27 
smoothend 478 67 79 45 31 87 
sonic hedgehog 239 7 16 7 2 8 
ve-cadherin 745 10 669 232 170 1414 
vegf D (figf) 51 16 22 18 10 6 
ventx1.1-a 11 4 9 10 4 1 
ventx2.1-b 45 2 13 14 7 2 
wnt11 213 8 11 1 1 21 
wnt8 8 3 2 2 8 2 
NEG_A 3 3 6 3 1 1 
NEG_B 6 3 3 4 3 1 
NEG_C 1 5 5 1 1 1 
NEG_D 4 4 3 5 4 1 
NEG_E 2 1 4 1 2 1 
NEG_F 4 2 3 2 1 4 
NEG_G 3 1 3 1 1 1 
NEG_H 4 4 7 2 2 1 
POS_A 8097 9727 11049 6552 5888 6252 
POS_B 4452 4739 5128 3583 3148 3313 
POS_C 1233 1317 1489 1032 887 872 
POS_D 256 251 323 186 175 165 
POS_E 58 63 64 55 46 31 













CE CC Etv2 Etv2/ MO2 Etv2 /mmMO1 Etv2 /Fam132b 
AT3-Globin 24226 11 6300 6879 2375 8 
Aplnr-a/b 965 49 465 109 313 2587 
BMP2-a/b 517 362 568 505 349 138 
BMP4-b 124 282 161 155 255 102 
BMP7.1 952 611 591 638 652 510 
BMP7.2 12 7 3 1 3 4 
Castor 244 27 38 32 26 31 
Cerberus 19 10 11 16 13 10 
FGF4b 10 6 13 6 4 4 
Fam32B 39 11 11 13 5 591 
Ferritin (fth1-a)) 24714 23290 27188 20539 29594 37435 
Ferroportin (slc40a1) 1913 3788 3117 2904 2619 1475 
Follistatin 878 13 25 14 14 307 
Foxc1a 426 41 41 24 68 73 
GATA-1-a 95 22 73 87 41 10 
GATA-2 323 324 387 411 240 117 
GATA-3 672 873 651 646 659 660 
Gli2 479 316 169 192 177 303 
Gli3 218 82 42 56 54 140 
Gli4 338 86 66 64 58 196 
H4 12 25 23 23 24 13 
HIF-1a 1042 634 655 655 553 672 
HIF-2a (epas1) 725 1334 725 685 570 504 
LMO-2 280 3 325 277 222 69 
Lmo4 351 67 114 119 132 118 
Mix2 470 2454 1579 1654 1596 594 
Msx2 1089 4572 2372 2155 2325 1603 
MyT1 1292 55 35 46 48 720 
NCAMa/b 1698 5 3 9 5 754 
Noggin 228 25 34 25 32 278 
ODC 30707 12170 11049 13103 10819 19765 
PECAM1 15 3 11 8 11 35 
Prox-1 582 11 66 52 57 31 
SCL 280 1 158 178 76 106 
SPIB-a 148 54 1469 1009 1256 89 
STAT-5 637 1762 986 997 1546 397 
Siamois 5 7 4 11 5 6 
Sizzled 92 112 299 209 222 75 
Sox2 2661 45 76 85 98 2559 
Sox3 684 26 22 19 36 537 
TGFB-1 627 43 159 146 85 218 






CE CC Etv2 Etv2/ MO2 Etv2 /mmMO1 Etv2 /Fam132b 
VEGFR-1 (Flt1) 97 7 25 7 8 135 
Vegfa-a/b 519 75 78 47 54 103 
Vent1 30 19 29 25 37 6 
Vent2 23 13 39 20 35 27 
Xbra-a 37 5 7 3 4 7 
Xbra-b 44 3 1 2 1 1 
Xhex 135 15 278 186 300 151 
Xnr3 8 8 9 4 9 3 
Xpo 1782 1097 1063 863 1336 863 
actb 145623 211552 179180 172366 194719 128701 
activin B 198 24 36 26 20 114 
admp2 9 7 7 9 8 9 
ami 2403 4 2431 401 801 13017 
angiopoitin (angpt1) 143 5 12 4 1 28 
apelin-a/b 322 6 38 15 30 47 
bFGF (fgf2) 156 22 19 12 24 68 
bmper 377 101 127 96 153 198 
chibby 8 7 9 6 6 2 
chordin 37 2 1 3 4 11 
ctroponin 147 11 3 11 5 7 
dkk-1 115 39 99 94 87 53 
dkk-2 43 15 6 15 10 16 
dkk-3 232 92 59 53 49 369 
egln1 (PHD2) 532 1026 345 274 473 165 
egln2 (PHD1) 26112 35713 30931 33722 27580 26829 
egln3 (PHD3) 58 54 74 63 57 60 
egr1-a/b 508 2098 1196 1636 1081 622 
endoglin 84 5 57 30 67 102 
epidermal Keratin 31658 112133 100861 104344 84504 68498 
epo 16 11 3 7 9 15 
epor 112 15 35 44 17 7 
er71/etv2 37 15 53 22 29 246 
erg-a (v-ets) 276 7 113 61 65 158 
fgfr-1 244 45 29 26 49 101 
fgfr-2 768 587 392 466 385 294 
fgfr-3 285 51 34 29 23 90 
fgfr-4 706 89 187 162 153 256 
flk-1 78 5 54 16 36 170 
g6pd 719 361 822 702 701 608 
gapdh 8700 7347 4923 5341 9563 886 
hand1 274 7 9 15 3 4 
hand2-a 753 251 142 164 141 130 
indian hedgehog (bhh) 65 5 5 3 5 4 






CE CC Etv2 Etv2/ MO2 Etv2 /mmMO1 Etv2 /Fam132b 
klf2 153 35 85 41 71 144 
lipase endothelial 92 77 48 67 51 23 
lysocardiolipin acyltransferase 1096 1277 969 1052 1263 618 
mespa-a/b 2 1 3 2 1 1 
mix1-b 3 6 6 7 1 2 
mpo 3680 2 15121 13637 14872 8 
myosin light chain 1 7045 2 2 3 1 4 
nkx2.5 116 25 30 43 31 249 
notch-1 1329 192 211 165 235 668 
nr2f2 (COUP.TFII) 569 22 23 13 14 136 
numb 335 553 415 438 596 245 
patched1 489 41 24 27 22 78 
patched2 1635 14 47 24 39 109 
pdgf-a 150 30 17 21 21 69 
phospholipase C gamma 1 (plcg1) 197 108 74 48 92 105 
runx1 97 179 639 416 530 106 
smad1-a 808 594 491 454 601 491 
smad5 (smad4.2-b) 58 75 25 28 32 31 
smoothend 464 123 78 66 68 163 
sonic hedgehog 173 2 7 5 10 4 
ve-cadherin 670 14 298 67 216 1499 
vegf D (figf) 91 23 28 20 27 11 
ventx1.1-a 8 17 13 15 14 1 
ventx2.1-b 64 21 56 35 50 32 
wnt11 201 3 2 1 2 59 
wnt8 10 4 3 7 6 6 
NEG_A 1 4 3 2 4 2 
NEG_B 2 1 1 1 2 1 
NEG_C 4 4 1 2 2 4 
NEG_D 1 5 5 4 3 4 
NEG_E 2 1 3 2 1 1 
NEG_F 2 4 3 2 1 3 
NEG_G 2 3 2 1 2 2 
NEG_H 6 5 4 3 2 3 
POS_A 7135 8574 5711 6265 7757 6373 
POS_B 3824 4561 3125 3602 3900 3954 
POS_C 1034 1246 884 974 1095 1094 
POS_D 200 255 143 177 207 210 
POS_E 52 48 39 46 47 27 







6.3 Processed data from Nanostring nCounter analysis 
 
Fold Changes over Etv2 for experiment 1 and experiment 2 were calculated. 
Averaged Fold Changes over Etv2 and standard errors for each sample and 
gene are shown in Table 11 and Table 12. 
 
Table 11.Averaged fold changes over Etv2 of two independent experiments. 
Gene 
averaged Fold Change over Etv2 
CC Etv2 Etv2/ MO2 Etv2 /mmMO1 Etv2 /Fam132b 
AT3-Globin 0,00 1 1,46 0,61 0,00 
Aplnr-a/b 0,05 1 0,19 0,47 2,52 
BMP2-a/b 0,59 1 0,87 0,90 0,19 
BMP4-b 1,36 1 0,57 1,20 0,35 
BMP7.1 0,97 1 0,81 1,00 0,52 
BMP7.2 1,17 1 1,00 1,00 1,00 
Castor 0,58 1 0,66 0,61 0,93 
Cerberus 0,72 1 0,83 0,82 0,18 
FGF4b 0,45 1 1,28 1,60 0,45 
Fam32B 0,86 1 3,89 1,39 1452,73 
Ferritin (fth1-a)) 0,95 1 0,78 1,59 0,75 
Ferroportin (slc40a1) 1,22 1 0,79 1,02 0,28 
Follistatin 0,22 1 0,22 0,27 5,38 
Foxc1a 0,96 1 0,44 1,33 1,02 
GATA-1-a 0,16 1 1,27 0,68 0,03 
GATA-2 0,78 1 1,09 1,06 0,64 
GATA-3 1,33 1 0,82 1,12 0,56 
Gli2 1,56 1 0,88 1,00 1,48 
Gli3 1,59 1 1,00 1,36 1,85 
Gli4 1,11 1 0,69 1,15 2,98 
H4 0,75 1 0,68 0,83 0,13 
HIF-1a 0,85 1 0,85 0,96 0,61 
HIF-2a (epas1) 1,77 1 0,85 1,00 0,40 
LMO-2 0,00 1 0,80 0,70 0,28 
Lmo4 0,47 1 0,80 0,86 0,72 
Mix2 1,48 1 0,87 1,09 0,21 
Msx2 1,57 1 0,71 1,00 0,41 
MyT1 1,32 1 1,07 1,27 9,89 
NCAMa/b 0,51 1 2,68 1,13 262,77 
Noggin 0,47 1 0,40 0,71 3,40 
ODC 1,00 1 1,00 1,00 1,00 
PECAM1 0,14 1 0,41 0,68 2,37 
Prox-1 0,10 1 0,69 0,89 0,43 
SCL 0,01 1 1,09 0,62 0,67 
SPIB-a 0,03 1 1,42 1,86 0,05 





averaged Fold Change over Etv2 
CC Etv2 Etv2/ MO2 Etv2 /mmMO1 Etv2 /Fam132b 
Siamois 1,17 1 4,22 1,72 1,00 
Sizzled 0,51 1 0,98 1,17 0,27 
Sox2 0,37 1 0,66 0,96 12,73 
Sox3 0,88 1 0,53 1,29 11,52 
TGFB-1 0,25 1 0,88 0,72 0,92 
VEGF C 0,44 1 0,85 0,97 0,70 
VEGFR-1 (Flt1) 0,05 1 0,24 0,27 2,73 
Vegfa-a/b 0,88 1 0,72 0,94 0,73 
Vent1 0,44 1 1,09 1,22 0,05 
Vent2 0,35 1 0,58 0,80 0,21 
Xbra-a 0,66 1 0,66 1,41 2,36 
Xbra-b 1,00 1 1,00 1,00 1,00 
Xhex 0,02 1 0,67 0,98 0,49 
Xnr3 0,62 1 0,89 2,19 0,49 
Xpo 1,17 1 0,81 1,19 0,41 
actb 1,05 1 0,94 1,28 0,46 
activin B 1,13 1 0,61 1,09 2,96 
admp2 0,43 1 1,07 1,21 0,44 
ami 0,00 1 0,31 0,36 2,54 
angiopoitin (angpt1) 0,55 1 0,55 0,55 7,50 
apelin-a/b 0,22 1 0,39 0,63 0,83 
bFGF (fgf2) 0,89 1 0,66 1,33 1,84 
bmper 0,56 1 0,65 0,94 0,97 
chibby 0,33 1 0,62 2,28 0,30 
chordin 0,72 1 0,72 1,04 2,33 
ctroponin 3,43 1 4,22 1,63 2,14 
dkk-1 0,51 1 0,67 0,91 0,17 
dkk-2 2,76 1 3,08 2,68 1,70 
dkk-3 1,22 1 0,65 0,78 4,19 
egln1 (PHD2) 2,00 1 0,57 1,08 0,32 
egln2 (PHD1) 1,20 1 0,88 1,05 0,39 
egln3 (PHD3) 0,76 1 0,94 1,24 0,92 
egr1-a/b 1,47 1 1,03 1,34 0,53 
endoglin 0,01 1 0,45 0,99 1,23 
epidermal Keratin 1,18 1 1,03 1,01 0,39 
epo 2,97 1 1,82 3,72 2,86 
epor 0,42 1 1,40 1,27 0,05 
er71/etv2 0,11 1 0,29 0,46 2,42 
erg-a (v-ets) 0,01 1 0,62 0,65 0,76 
fgfr-1 1,12 1 0,54 1,24 1,60 
fgfr-2 1,28 1 0,97 1,03 0,52 
fgfr-3 1,05 1 0,51 0,54 1,69 
fgfr-4 0,35 1 0,71 0,74 1,02 





averaged Fold Change over Etv2 
CC Etv2 Etv2/ MO2 Etv2 /mmMO1 Etv2 /Fam132b 
g6pd 0,55 1 1,41 2,34 0,45 
gapdh 1,40 1 0,65 1,40 0,08 
hand1 0,21 1 1,37 0,31 0,18 
hand2-a 1,48 1 1,09 1,08 0,64 
indian hedgehog (bhh) 0,72 1 0,72 1,34 0,72 
jagged-1 0,75 1 0,56 0,96 1,34 
klf2 0,26 1 0,32 0,82 1,29 
lipase endothelial 0,96 1 0,94 0,97 0,18 
lysocardiolipin acyltransferase 1,28 1 0,92 1,25 0,40 
mespa-a/b 1,00 1 1,00 1,00 1,00 
mix1-b 0,76 1 2,29 0,76 0,76 
mpo 0,00 1 1,25 1,37 0,00 
myosin light chain 1 0,50 1 0,50 0,50 0,51 
nkx2.5 1,09 1 2,70 2,48 8,61 
notch-1 0,64 1 0,63 0,96 1,94 
nr2f2 (COUP.TFII) 0,60 1 0,28 0,47 4,09 
numb 1,26 1 0,87 1,25 0,34 
patched1 1,15 1 0,60 0,71 1,73 
patched2 0,09 1 0,26 0,52 1,32 
pdgf-a 1,18 1 0,72 1,20 2,31 
phospholipase C gamma 1 (plcg1) 0,93 1 0,39 0,90 0,95 
runx1 0,25 1 0,83 0,89 0,18 
smad1-a 1,07 1 0,79 1,14 0,60 
smad5 (smad4.2-b) 2,20 1 0,71 1,14 0,74 
smoothend 1,05 1 0,59 0,69 1,20 
sonic hedgehog 0,21 1 0,23 1,40 0,44 
ve-cadherin 0,01 1 0,24 0,52 2,53 
vegf D (figf) 0,56 1 0,63 0,79 0,15 
ventx1.1-a 0,81 1 1,38 0,90 0,26 
ventx2.1-b 0,21 1 0,82 0,85 0,21 
wnt11 0,61 1 0,61 0,61 20,33 
wnt8 1,00 1 2,12 5,00 1,00 
 
Table 12. Standard errors of the fold change over Etv2 shown in Table 11. 
Gene 
standard error 
CC Etv2 Etv2/ MO2 Etv2 /mmMO1 Etv2 /Fam132b 
AT3-Globin 0,00 0 0,54 0,22 0,00 
Aplnr-a/b 0,03 0 0,00 0,21 0,61 
BMP2-a/b 0,01 0 0,12 0,27 0,06 
BMP4-b 0,24 0 0,24 0,44 0,01 
BMP7.1 0,03 0 0,11 0,13 0,05 
BMP7.2 0,17 0 0,00 0,00 0,00 
Castor 0,01 0 0,04 0,09 0,53 






CC Etv2 Etv2/ MO2 Etv2 /mmMO1 Etv2 /Fam132b 
FGF4b 0,36 0 1,07 1,50 0,36 
Fam32B 0,14 0 2,72 1,11 1402,95 
Ferritin (fth1-a)) 0,17 0 0,14 0,47 0,02 
Ferroportin (slc40a1) 0,11 0 0,01 0,16 0,01 
Follistatin 0,10 0 0,19 0,26 2,77 
Foxc1a 0,09 0 0,02 0,48 0,01 
GATA-1-a 0,05 0 0,25 0,12 0,00 
GATA-2 0,02 0 0,19 0,43 0,48 
GATA-3 0,11 0 0,02 0,09 0,01 
Gli2 0,15 0 0,08 0,07 0,48 
Gli3 0,25 0 0,17 0,02 0,13 
Gli4 0,07 0 0,13 0,24 1,26 
H4 0,19 0 0,19 0,32 0,05 
HIF-1a 0,03 0 0,00 0,10 0,04 
HIF-2a (epas1) 0,10 0 0,05 0,20 0,01 
LMO-2 0,00 0 0,08 0,00 0,17 
Lmo4 0,04 0 0,08 0,34 0,16 
Mix2 0,06 0 0,02 0,06 0,00 
Msx2 0,18 0 0,06 0,00 0,03 
MyT1 0,14 0 0,09 0,23 3,16 
NCAMa/b 0,49 0 2,66 1,12 256,98 
Noggin 0,12 0 0,20 0,28 1,72 
ODC 0,00 0 0,00 0,00 0,00 
PECAM1 0,01 0 0,11 0,53 0,01 
Prox-1 0,03 0 0,03 0,01 0,22 
SCL 0,00 0 0,13 0,13 0,31 
SPIB-a 0,00 0 0,84 0,98 0,01 
STAT-5 0,32 0 0,06 0,09 0,01 
Siamois 0,17 0 3,22 0,53 0,00 
Sizzled 0,18 0 0,39 0,41 0,14 
Sox2 0,13 0 0,30 0,39 7,20 
Sox3 0,16 0 0,19 0,61 5,36 
TGFB-1 0,03 0 0,10 0,18 0,16 
VEGF C 0,13 0 0,25 0,33 0,07 
VEGFR-1 (Flt1) 0,01 0 0,12 0,03 0,75 
Vegfa-a/b 0,03 0 0,23 0,23 0,00 
Vent1 0,05 0 0,37 0,19 0,02 
Vent2 0,16 0 0,18 0,14 0,11 
Xbra-a 0,34 0 0,34 1,09 2,04 
Xbra-b 0,00 0 0,00 0,00 0,00 
Xhex 0,01 0 0,11 0,12 0,20 
Xnr3 0,19 0 0,72 0,90 0,32 
Xpo 0,23 0 0,13 0,10 0,04 






CC Etv2 Etv2/ MO2 Etv2 /mmMO1 Etv2 /Fam132b 
activin B 0,61 0 0,02 0,55 1,06 
admp2 0,01 0 0,61 0,70 0,01 
ami 0,00 0 0,17 0,02 0,45 
angiopoitin (angpt1) 0,45 0 0,45 0,45 5,95 
apelin-a/b 0,20 0 0,11 0,19 0,16 
bFGF (fgf2) 0,12 0 0,19 0,13 0,50 
bmper 0,14 0 0,01 0,31 0,10 
chibby 0,10 0 0,24 1,66 0,13 
chordin 0,28 0 0,28 0,04 0,43 
ctroponin 2,43 0 3,22 0,63 1,14 
dkk-1 0,19 0 0,13 0,01 0,11 
dkk-2 2,58 0 2,90 1,75 1,52 
dkk-3 0,21 0 0,11 0,08 0,49 
egln1 (PHD2) 0,72 0 0,10 0,33 0,06 
egln2 (PHD1) 0,15 0 0,04 0,14 0,09 
egln3 (PHD3) 0,13 0 0,22 0,45 0,49 
egr1-a/b 0,12 0 0,12 0,41 0,24 
endoglin 0,00 0 0,03 0,25 0,22 
epidermal Keratin 0,17 0 0,16 0,16 0,01 
epo 2,89 0 1,42 3,62 2,69 
epor 0,15 0 0,30 0,81 0,03 
er71/etv2 0,06 0 0,02 0,08 0,33 
erg-a (v-ets) 0,00 0 0,17 0,07 0,01 
fgfr-1 0,33 0 0,22 0,66 0,54 
fgfr-2 0,08 0 0,04 0,02 0,11 
fgfr-3 0,34 0 0,21 0,15 0,12 
fgfr-4 0,06 0 0,02 0,10 0,26 
flk-1 0,00 0 0,06 0,20 0,29 
g6pd 0,16 0 0,69 1,47 0,03 
gapdh 0,05 0 0,27 0,58 0,02 
hand1 0,03 0 0,68 0,14 0,00 
hand2-a 0,14 0 0,11 0,06 0,14 
indian hedgehog (bhh) 0,28 0 0,28 0,91 0,28 
jagged-1 0,03 0 0,06 0,29 0,01 
klf2 0,07 0 0,07 0,04 0,34 
lipase endothelial 0,52 0 0,28 0,15 0,03 
lysocardiolipin acyltransferase 0,08 0 0,00 0,08 0,04 
mespa-a/b 0,00 0 0,00 0,00 0,00 
mix1-b 0,24 0 0,62 0,24 0,24 
mpo 0,00 0 0,49 0,37 0,00 
myosin light chain 1 0,50 0 0,50 0,50 0,49 
nkx2.5 0,41 0 1,41 1,37 3,32 
notch-1 0,18 0 0,02 0,19 0,15 






CC Etv2 Etv2/ MO2 Etv2 /mmMO1 Etv2 /Fam132b 
numb 0,05 0 0,02 0,23 0,02 
patched1 0,49 0 0,39 0,27 0,30 
patched2 0,08 0 0,14 0,33 0,02 
pdgf-a 0,56 0 0,43 0,24 0,45 
phospholipase C gamma 1 (plcg1) 0,40 0 0,15 0,40 0,17 
runx1 0,00 0 0,28 0,04 0,10 
smad1-a 0,03 0 0,01 0,12 0,04 
smad5 (smad4.2-b) 0,86 0 0,28 0,29 0,09 
smoothend 0,40 0 0,12 0,21 0,01 
sonic hedgehog 0,11 0 0,13 1,30 0,12 
ve-cadherin 0,01 0 0,06 0,22 0,31 
vegf D (figf) 0,10 0 0,05 0,24 0,05 
ventx1.1-a 0,38 0 0,28 0,39 0,17 
ventx2.1-b 0,06 0 0,31 0,07 0,06 
wnt11 0,39 0 0,39 0,39 15,83 
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